<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part5">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>5</PartID>
        <PartNumber>Part IV</PartNumber>
        <PartSequenceNumber>5</PartSequenceNumber>
        <PartTitle>Bone Metastasis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap26" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>26</ChapterID>
          <ChapterNumber>Chapter 26</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_26</ChapterDOI>
          <ChapterSequenceNumber>26</ChapterSequenceNumber>
          <ChapterTitle Language="En">Calcitriol and Vitamin D Analogs</ChapterTitle>
          <ChapterFirstPage>287</ChapterFirstPage>
          <ChapterLastPage>302</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>5</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Ana</GivenName>
                <GivenName>R.</GivenName>
                <FamilyName>Jensen</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Russell</GivenName>
                <GivenName>Z.</GivenName>
                <FamilyName>Szmulewitz</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Tomasz</GivenName>
                <GivenName>M.</GivenName>
                <FamilyName>Beer</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_26" CorrespondingAffiliationID="Aff1_26">
              <AuthorName DisplayOrder="Western">
                <GivenName>Edwin</GivenName>
                <GivenName>M.</GivenName>
                <FamilyName>Posadas</FamilyName>
              </AuthorName>
              <Contact>
                <Email>eposadas@bsd.uchicago.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_26">
              <OrgDivision>Section of Hematology/Oncology, Department of Medicine</OrgDivision>
              <OrgName>University of Chicago</OrgName>
              <OrgAddress>
                <City>Chicago</City>
                <State>IL</State>
                <Postcode>60637</Postcode>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_26" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Calcitriol (1,25-dihydroxycholecaliferol) is a synthetic analog of vitamin D that is physiologically active in absorption of calcium from the gastrointestinal tract. Recent clinical and laboratory developments have fueled enthusiasm for studying the role of vitamin D and its relationship to oncogenesis and malignant progression. There are epidemiological data pointing toward a link between vitamin D and prostate cancer as well as preclinical and clinical data linking antineoplastic activity of vitamin D receptor ligands with prostate cancer. As such, efforts have been geared toward the development of vitamin D receptor ligand-based therapy for early and advanced prostate cancer. In this chapter we will discuss the historic and current thoughts on the role that vitamin D may play in prostate cancer risk and treatment.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Vitamin D</Keyword>
            <Keyword>Calcitriol</Keyword>
            <Keyword>Vitamin D receptor</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>Epidemiology of Vitamin D and Prostate Cancer</Heading>
            <Section2 ID="Sec2">
              <Heading>Prostate Cancer Risk</Heading>
              <Para TextBreak="No">A growing literature has identified vitamin D and calcium as risk factors for prostate cancer (CaP). Traditionally, a number of factors have been associated with increased risk of prostate cancer including advanced age, African genetic heritage, and residence in northern latitudes. These same factors have been associated with lower levels of vitamin D and have served as a rationale for the hypothesis that vitamin D played a critical role in the maintenance of the normal phenotype of prostate epithelial cells.</Para>
              <Para TextBreak="No">The evidence linking low vitamin D levels with prostate cancer has been mixed. The global pattern of greater risk in northern regions led investigators to suggest that reduced exposure to solar UV radiation and consequent reduction in endogenous vitamin D production may be associated with an increased risk of CaP [<CitationRef CitationID="CR1_26">1</CitationRef>]. A case-control study from the UK showed a reduced risk with greater UV exposure [<CitationRef CitationID="CR2_26">2</CitationRef>]. In a US study, there was only a weak link between average regional UV-B radiation and prostate cancer mortality [<CitationRef CitationID="CR3_26">3</CitationRef>]. Studies that examined 25-hydroxy vitamin D (25-OH vitamin D) levels in populations with a low prevalence of severe vitamin D deficiency did not reveal a relationship between vitamin D blood levels and prostate cancer risk [<CitationRef CitationID="CR4_26">4</CitationRef>–<CitationRef CitationID="CR8_26">8</CitationRef>]. Studies conducted in Nordic countries, where severe vitamin D deficiency is more common [<CitationRef CitationID="CR9_26">9</CitationRef>, <CitationRef CitationID="CR10_26">10</CitationRef>], reported increased risk in men with the lowest vitamin D levels, although one of the studies [<CitationRef CitationID="CR10_26">10</CitationRef>] also suggested an increased risk at the highest levels. Two studies suggest that low 1,25-dihydroxy vitamin D (1,25-OH<Subscript>2</Subscript> vitamin D) levels were associated with an increased risk of aggressive prostate cancer [<CitationRef CitationID="CR4_26">4</CitationRef>, <CitationRef CitationID="CR5_26">5</CitationRef>], but overall CaP risk was not associated with 1,25-OH<Subscript>2</Subscript> vitamin D in two recent, relatively small studies [<CitationRef CitationID="CR6_26">6</CitationRef>, <CitationRef CitationID="CR8_26">8</CitationRef>]. To date, studies that examined dietary vitamin D intake have not revealed a protective effect from prostate cancer [<CitationRef CitationID="CR11_26">11</CitationRef>–<CitationRef CitationID="CR15_26">15</CitationRef>]. A meta-analysis of more than 26,000 patients in 45 studies published in 2008 did not show any strong protective effect associated with vitamin D consumption (RR = 1.16; 95% CI = 0.98–1.38) [<CitationRef CitationID="CR16_26">16</CitationRef>].</Para>
              <Para TextBreak="No">A number of studies have examined the role of dairy product consumption and prostate cancer risk that may be mediated through vitamin D. A 2004 meta-analysis of 11 case control studies reported a combined odds ratio of 1.68 for high milk consumption and prostate cancer [<CitationRef CitationID="CR17_26">17</CitationRef>]. Giovanucci et al. have suggested that loss of 1-α hydroxylase activity in prostate cancer cells may explain these epidemiologic findings. Normal prostate epithelial cells or colon cancer cells [<CitationRef CitationID="CR18_26">18</CitationRef>, <CitationRef CitationID="CR19_26">19</CitationRef>] express 1-a hydroxylase and can therefore convert 25-OH vitamin D to the active 1,25-OH<Subscript>2</Subscript> vitamin D. This activity can be lost when the cancer develops [<CitationRef CitationID="CR20_26">20</CitationRef>, <CitationRef CitationID="CR21_26">21</CitationRef>]. The loss of this activity would be expected to render prostate cancer resistant to 25-OH vitamin D and dependent on circulating 1,25-OH<Subscript>2</Subscript> vitamin D for vitamin D receptor (VDR)-mediated activity. Circulating 1,25-OH<Subscript>2</Subscript> vitamin D levels are tightly controlled and largely unaffected by 25-OH vitamin D levels except for a severe deficiency state [<CitationRef CitationID="CR22_26">22</CitationRef>–<CitationRef CitationID="CR25_26">25</CitationRef>]. If this hypothesis proves correct, it would not be surprising that 25-OH vitamin D levels or behaviors that influence them (sunlight, vitamin D supplements) would have little effect on prostate cancer except in the extremes. At the same time, high milk and high calcium consumption are associated with a significant reduction in circulating 1,25-OH<Subscript>2</Subscript> vitamin D levels [<CitationRef CitationID="CR26_26">26</CitationRef>]. This reduction in circulating 1,25-OH<Subscript>2</Subscript> vitamin D levels could explain excess risk. Beer et al. showed that vitamin D receptors are universally expressed in human prostate cancer specimens and that preprostatectomy high-dose 1,25-OH<Subscript>2</Subscript> vitamin D treatment significantly reduces VDR expression in human prostate tumors [<CitationRef CitationID="CR27_26">27</CitationRef>]. This finding is consistent with the hypothesis advanced by Giovanucci.</Para>
              <Para TextBreak="No">VDR and binding protein (DBP) have also been implicated in the recognized racial disparities that exist in the population of men affected by CaP. In a case-control study of single nucleotide polymorphisms (SNPs) of VDR and DBP, African-American men who possessed at least one variant allele VDR-5132C had an increased risk of CaP (OR=1.83; 95% CI: 1.02, 3.31) [<CitationRef CitationID="CR28_26">28</CitationRef>]. The impact of VDR genetic variations is not limited to patients of African descent. Torkko et al. identified VDR mutations in concert with mutation in 5-a reductase that have been correlated with higher risk of CaP in Hispanic and non-Hispanic Caucasians [<CitationRef CitationID="CR29_26">29</CitationRef>]. These data and other studies of this nature point to the importance of vitamin D signaling in prostate cancer development, though much needs to be done to understand the final definitive pathways through which these risks are imparted.</Para>
            </Section2>
            <Section2 ID="Sec3">
              <Heading>Prostate Cancer Outcomes</Heading>
              <Para TextBreak="No">Several investigators have recently reported that the season of diagnosis and treatment and vitamin D blood levels are important predictors of outcome in several cancer types including prostate cancer. Zhou et al. found that patients diagnosed and surgically treated for nonsmall cell lung cancer during the summer had a better relapse-free survival than patients diagnosed and treated in the winter. The greatest difference was seen when patients who had surgery in the summer and had a high intake of vitamin D were compared with patients operated on in the winter, who had low vitamin D intake (HR 0.33, 95% CI 0.15–0.74). A similar association for overall survival was also noted [<CitationRef CitationID="CR30_26">30</CitationRef>]. In a Norwegian study of 115,096 breast-, colon-, and prostate cancer patients, Robsahm et al. found that those diagnosed in the summer or fall had significantly lower case fatality rates than similar patients diagnosed in the winter and spring [<CitationRef CitationID="CR31_26">31</CitationRef>]. For CaP, the season of diagnosis was associated with a statistically significant 20–30% reduction in risk of death. Lagunova et al. performed a prostate cancer-specific analysis in the Norwegian population and showed a similar variation in relative risk favoring those patients diagnosed in the summer and fall over those diagnosed in the winter and spring [relative risk (RR) of death 0.8; 95% CI 0.75–0.85] [<CitationRef CitationID="CR32_26">32</CitationRef>]. The study controlled for UV exposure, rates of squamous cell carcinoma of the skin, and fish intake. Little variation was seen across age. The authors suggested that the effect may be related to variations in vitamin D intake and activity. There are no prospective studies of vitamin D supplementation or treatment with surgery or radiation for prostate cancer, but the emerging retrospective data are intriguing.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Mechanisms of Antineoplastic Activity in Preclinical Systems</Heading>
            <Section2 ID="Sec5">
              <Heading>Vitamin D Signaling</Heading>
              <Para TextBreak="No">Vitamin D signaling involves both receptor-mediated genomic and nongenomic pathways. The VDR, the mediator of the classic genomic response, is a steroid hormone receptor and acts as a ligand-activated transcription factor [<CitationRef CitationID="CR33_26">33</CitationRef>]. It binds to the vitamin D response elements (VDRE) present in the regulatory region of many genes after forming a heterodimer with the retinoid-X receptor (RXR) and in some cases the retinoid A receptor (RAR) [<CitationRef CitationID="CR34_26">34</CitationRef>–<CitationRef CitationID="CR36_26">36</CitationRef>]. In the presence of coactivator complexes, the VDR heterodimer interacts with the RNA polymerase complex and initiates gene transcription. The number of genes that are recognized to have a functional VDRE is rapidly growing. Examples include a number of bone-associated genes such as osteocalcin [<CitationRef CitationID="CR37_26">37</CitationRef>], osteopontin [<CitationRef CitationID="CR38_26">38</CitationRef>], bone sialoprotein [<CitationRef CitationID="CR39_26">39</CitationRef>], receptor activator of NF-κB ligand (RANKL) [<CitationRef CitationID="CR40_26">40</CitationRef>], Runx2/Cbfa1 [<CitationRef CitationID="CR41_26">41</CitationRef>], tumor necrosis factor alpha [<CitationRef CitationID="CR42_26">42</CitationRef>], parathyroid hormone [<CitationRef CitationID="CR43_26">43</CitationRef>], parathyroid hormone-related protein [<CitationRef CitationID="CR44_26">44</CitationRef>], the insulin receptor [<CitationRef CitationID="CR45_26">45</CitationRef>], insulin-induced gene-2 [<CitationRef CitationID="CR46_26">46</CitationRef>], carbonic anhydrase II [<CitationRef CitationID="CR47_26">47</CitationRef>], human growth hormone [<CitationRef CitationID="CR48_26">48</CitationRef>], the calcium-binding proteins calbindin-D28k and D9k [<CitationRef CitationID="CR49_26">49</CitationRef>], fructose 1,6-bisphosphatase [<CitationRef CitationID="CR50_26">50</CitationRef>], the cell cycle regulators p21 [<CitationRef CitationID="CR51_26">51</CitationRef>], GADD45 [<CitationRef CitationID="CR52_26">52</CitationRef>], and IGFBP3 [<CitationRef CitationID="CR53_26">53</CitationRef>, <CitationRef CitationID="CR54_26">54</CitationRef>], 25(OH)D3 24-hydroxylase [<CitationRef CitationID="CR55_26">55</CitationRef>], cytochrome P450 3A4 (CYP3A4) [<CitationRef CitationID="CR56_26">56</CitationRef>], organic anion transporter MRP3 [<CitationRef CitationID="CR57_26">57</CitationRef>], epidermal growth factor receptor (EGFR) [<CitationRef CitationID="CR58_26">58</CitationRef>], c-fos [<CitationRef CitationID="CR59_26">59</CitationRef>], phospholipase C [<CitationRef CitationID="CR60_26">60</CitationRef>], as well as a number of genes that regulate cell adhesion and differentiation such as fibronectin [<CitationRef CitationID="CR61_26">61</CitationRef>], <Emphasis Type="Italic">β</Emphasis>3 integrin [<CitationRef CitationID="CR62_26">62</CitationRef>], and involucrin [<CitationRef CitationID="CR63_26">63</CitationRef>]. Interestingly, several of these genes have been implicated in prostate cancer or prostate cancer metastases [<CitationRef CitationID="CR64_26">64</CitationRef>–<CitationRef CitationID="CR66_26">66</CitationRef>]. In addition to the classic genomic response, vitamin D also induces rapid nontranscriptional signals leading to increases in calcium and phosphate uptake in intestinal cells [<CitationRef CitationID="CR67_26">67</CitationRef>] and the opening of Ca<Superscript>2+</Superscript>-dependent K<Superscript>+</Superscript>- and voltage-gated calcium and chloride channels in kidney proximal tubules and skeletal muscle, respectively [<CitationRef CitationID="CR68_26">68</CitationRef>, <CitationRef CitationID="CR69_26">69</CitationRef>]. Rapid vitamin D-induced nongenomic signals also include the regulation of protein kinase C [<CitationRef CitationID="CR70_26">70</CitationRef>–<CitationRef CitationID="CR72_26">72</CitationRef>], ras, and mitogen-activated protein kinase (MAPK) [<CitationRef CitationID="CR70_26">70</CitationRef>, <CitationRef CitationID="CR73_26">73</CitationRef>–<CitationRef CitationID="CR76_26">76</CitationRef>], protein lipase A and prostaglandins [<CitationRef CitationID="CR77_26">77</CitationRef>, <CitationRef CitationID="CR78_26">78</CitationRef>], cyclic AMP and protein kinase A [<CitationRef CitationID="CR79_26">79</CitationRef>, <CitationRef CitationID="CR80_26">80</CitationRef>], phosphatidyl inositol 3-kinase/Akt [<CitationRef CitationID="CR81_26">81</CitationRef>, <CitationRef CitationID="CR82_26">82</CitationRef>], and the ceramide pathway [<CitationRef CitationID="CR83_26">83</CitationRef>]. Ultimately these responses regulate cellular growth, differentiation, and apoptosis [<CitationRef CitationID="CR73_26">73</CitationRef>, <CitationRef CitationID="CR74_26">74</CitationRef>, <CitationRef CitationID="CR84_26">84</CitationRef>, <CitationRef CitationID="CR85_26">85</CitationRef>]. They may also be mediated by the translocation of the VDR to the plasma membrane, cytosolic VDR, or by other unknown receptors [<CitationRef CitationID="CR73_26">73</CitationRef>, <CitationRef CitationID="CR86_26">86</CitationRef>–<CitationRef CitationID="CR91_26">91</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Spectrum of Activity</Heading>
              <Para TextBreak="No">After Abe et al. reported that calcitriol induced terminal differentiation in myeloid leukemia cells [<CitationRef CitationID="CR92_26">92</CitationRef>], a number of investigators reported in vitro and/or in vivo activity in models of a broad range of human neoplasms including carcinoma of the bladder [<CitationRef CitationID="CR93_26">93</CitationRef>], breast [<CitationRef CitationID="CR94_26">94</CitationRef>], colon [<CitationRef CitationID="CR95_26">95</CitationRef>], endometrium [<CitationRef CitationID="CR96_26">96</CitationRef>], kidney [<CitationRef CitationID="CR97_26">97</CitationRef>, <CitationRef CitationID="CR98_26">98</CitationRef>], lung [<CitationRef CitationID="CR99_26">99</CitationRef>], pancreas [<CitationRef CitationID="CR100_26">100</CitationRef>], prostate [<CitationRef CitationID="CR101_26">101</CitationRef>–<CitationRef CitationID="CR107_26">107</CitationRef>], sarcomas of the soft tissues [<CitationRef CitationID="CR108_26">108</CitationRef>], and bone [<CitationRef CitationID="CR109_26">109</CitationRef>, <CitationRef CitationID="CR110_26">110</CitationRef>], neuroblastoma [<CitationRef CitationID="CR111_26">111</CitationRef>, <CitationRef CitationID="CR112_26">112</CitationRef>], glioma [<CitationRef CitationID="CR113_26">113</CitationRef>], melanoma [<CitationRef CitationID="CR114_26">114</CitationRef>], squamous cell carcinoma [<CitationRef CitationID="CR115_26">115</CitationRef>, <CitationRef CitationID="CR116_26">116</CitationRef>], and others. Vitamin D signaling is likely to be important throughout organ systems as VDR appears to be expressed in nearly all human tissues [<CitationRef CitationID="CR117_26">117</CitationRef>, <CitationRef CitationID="CR118_26">118</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Mechanisms of Antineoplastic Activity</Heading>
            <Para TextBreak="No">Several mechanisms of activity have been demonstrated in preclinical systems, but given that vitamin D targets a broad range of genes, it is not surprising that the observed mechanisms vary under different experimental conditions and in different tumor models. It is likely that more than one of these mechanisms of activity is important in humans, and indeed different mechanisms may be important in different human diseases or at different stages of a human disease.</Para>
            <Section2 ID="Sec8">
              <Heading>Differentiation and Inhibition of Proliferation</Heading>
              <Para TextBreak="No">Inhibition of proliferation, which is associated with differentiation in some tumor models, has been extensively studied. In numerous cell lines, growth arrest in response to vitamin D occurs in the G1 phase of the cell cycle [<CitationRef CitationID="CR51_26">51</CitationRef>, <CitationRef CitationID="CR119_26">119</CitationRef>–<CitationRef CitationID="CR122_26">122</CitationRef>]. In several tumor models, the G1 growth arrest has been linked to transcriptional activation of cyclin-dependent kinase (CDK) inhibitors p27<Superscript>Kip1</Superscript> and p21<Superscript>Waf1</Superscript> [<CitationRef CitationID="CR51_26">51</CitationRef>, <CitationRef CitationID="CR121_26">121</CitationRef>]. These effects are not universally observed. For example, p21<Superscript>Waf1</Superscript> expression increases after 24 h and is reduced at 72 h in PC-3 prostate cancer cells, suggesting a biphasic, time-dependent response [<CitationRef CitationID="CR123_26">123</CitationRef>]. Induction of p27, which in contrast to p21 lacks a VDRE, appears to be mediated by NF-Y and SP1 [<CitationRef CitationID="CR124_26">124</CitationRef>, <CitationRef CitationID="CR125_26">125</CitationRef>]. Thus, additional effects may take place at the level of protein stability [<CitationRef CitationID="CR126_26">126</CitationRef>, <CitationRef CitationID="CR127_26">127</CitationRef>]. Dephosphorylation of the retinoblastoma protein in response to vitamin D has also been reported in both normal human keratinocytes [<CitationRef CitationID="CR128_26">128</CitationRef>] and several preclinical tumor models [<CitationRef CitationID="CR115_26">115</CitationRef>, <CitationRef CitationID="CR129_26">129</CitationRef>–<CitationRef CitationID="CR132_26">132</CitationRef>]. Vitamin D has been shown to inhibit other mitogenic signals including the ERK/MAPK pathway [<CitationRef CitationID="CR73_26">73</CitationRef>, <CitationRef CitationID="CR75_26">75</CitationRef>], c-myc [<CitationRef CitationID="CR133_26">133</CitationRef>, <CitationRef CitationID="CR134_26">134</CitationRef>], EGFR [<CitationRef CitationID="CR135_26">135</CitationRef>], and the insulin-like growth factor (IGF) system [<CitationRef CitationID="CR136_26">136</CitationRef>–<CitationRef CitationID="CR138_26">138</CitationRef>]. Vitamin D has also been shown to induce transforming growth factor-beta (TGF<Emphasis Type="Italic">β</Emphasis>) [<CitationRef CitationID="CR139_26">139</CitationRef>, <CitationRef CitationID="CR140_26">140</CitationRef>]. These effects vary across tumor models. While cell differentiation accompanies growth inhibition in some experimental systems, this association is not universal and differentiation can occur even in cells resistant to vitamin D-mediated growth arrest [<CitationRef CitationID="CR141_26">141</CitationRef>, <CitationRef CitationID="CR142_26">142</CitationRef>]. Vitamin D inhibits fatty acid synthase (FAS) expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 (FACL3) in LNCaP cells. The upregulation of FACL3 and subsequent inhibition of FAS are involved in the antiproliferative effects of vitamin D [<CitationRef CitationID="CR143_26">143</CitationRef>]. Interestingly, the growth inhibitory effects of vitamin D on LNCaP cells are significantly attenuated by an inhibitor of FACL3 activity. Further, vitamin D is unable to regulate FACL3 expression in the absence of androgens, indicating that the upregulation of FACL3 expression by vitamin D is mediated through the androgen receptor (AR) signaling pathway [<CitationRef CitationID="CR144_26">144</CitationRef>]. Relevant to prostate cancer, androgen signaling may be important for vitamin D-mediated growth inhibition in human prostate cancer cells. In LNCaP cells and CWR22R cells, vitamin D induces AR expression. Vitamin D-mediated growth inhibition is reduced when AR signaling is blocked by antiandrogens, RNA interference, or targeted disruption of the AR [<CitationRef CitationID="CR145_26">145</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>Apoptosis</Heading>
              <Para TextBreak="No">Vitamin D-induced apoptosis has been demonstrated in several prostate cancer models [<CitationRef CitationID="CR146_26">146</CitationRef>, <CitationRef CitationID="CR147_26">147</CitationRef>]. Vitamin D has been reported to downregulate the antiapoptotic protein Bcl-2 in prostate cancer [<CitationRef CitationID="CR146_26">146</CitationRef>] and several other neoplastic cell types [<CitationRef CitationID="CR75_26">75</CitationRef>, <CitationRef CitationID="CR147_26">147</CitationRef>–<CitationRef CitationID="CR154_26">154</CitationRef>]. In several cell lines, vitamin D-mediated apoptosis is independent of p53 status [<CitationRef CitationID="CR150_26">150</CitationRef>, <CitationRef CitationID="CR155_26">155</CitationRef>, <CitationRef CitationID="CR156_26">156</CitationRef>], although data about the role of p53 in this setting are not entirely consistent [<CitationRef CitationID="CR149_26">149</CitationRef>, <CitationRef CitationID="CR157_26">157</CitationRef>]. In the CaP cell lines LNCaP and ALVA-31, as well as in the MCF-7 breast cancer cells, vitamin D stimulates cytochrome ***c release from mitochondria by a caspase-independent mechanism [<CitationRef CitationID="CR146_26">146</CitationRef>, <CitationRef CitationID="CR158_26">158</CitationRef>]. Proapoptotic effects of vitamin D may also involve downregulation of the IGF receptor [<CitationRef CitationID="CR159_26">159</CitationRef>], upregulation of MEK kinase-1 [<CitationRef CitationID="CR116_26">116</CitationRef>], activation of the sphingomyelin-ceramide-ganglioside GD3 signaling pathway [<CitationRef CitationID="CR83_26">83</CitationRef>], downregulation of Akt [<CitationRef CitationID="CR160_26">160</CitationRef>, <CitationRef CitationID="CR161_26">161</CitationRef>], stimulation of TNF-<Emphasis Type="Italic">α</Emphasis> activity [<CitationRef CitationID="CR162_26">162</CitationRef>], induction of TGF-<Emphasis Type="Italic">β</Emphasis> signaling [<CitationRef CitationID="CR163_26">163</CitationRef>], and cytosolic calcium mobilization [<CitationRef CitationID="CR164_26">164</CitationRef>, <CitationRef CitationID="CR165_26">165</CitationRef>]. Induction of ovarian cancer cell apoptosis by vitamin D is mediated through downregulation of telomerase [<CitationRef CitationID="CR166_26">166</CitationRef>]. Although proapoptotic activity has been demonstrated in multiple experimental systems, these effects are not universal and vitamin D-induced inhibition of apoptosis has also been described. For example, vitamin D inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes [<CitationRef CitationID="CR167_26">167</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>Angiogenesis and Invasiveness</Heading>
              <Para TextBreak="No">Several investigators have also reported antiangiogenic and anti-invasive effects of vitamin D in preclinical tumor models. Proliferation of tumor-derived endothelial cells [<CitationRef CitationID="CR161_26">161</CitationRef>] and sprouting and elongation of endothelial cells induced by vascular endothelial growth factor [<CitationRef CitationID="CR168_26">168</CitationRef>] are inhibited in in vitro models of angiogenesis. Antiangiogenic activity has been confirmed in mouse tumor models [<CitationRef CitationID="CR168_26">168</CitationRef>, <CitationRef CitationID="CR169_26">169</CitationRef>]. Reduction of metastases with vitamin D therapy has been demonstrated in rodent models including those of prostate cancer [<CitationRef CitationID="CR93_26">93</CitationRef>, <CitationRef CitationID="CR101_26">101</CitationRef>, <CitationRef CitationID="CR170_26">170</CitationRef>], and reduced invasiveness has been shown in in vitro assays using prostate cancer [<CitationRef CitationID="CR171_26">171</CitationRef>–<CitationRef CitationID="CR173_26">173</CitationRef>], as well as a number of other tumor types [<CitationRef CitationID="CR174_26">174</CitationRef>, <CitationRef CitationID="CR175_26">175</CitationRef>]. Serine proteinase and metalloproteinase inhibition [<CitationRef CitationID="CR171_26">171</CitationRef>, <CitationRef CitationID="CR173_26">173</CitationRef>, <CitationRef CitationID="CR176_26">176</CitationRef>], decreased <Emphasis Type="Italic">α</Emphasis>6 and <Emphasis Type="Italic">β</Emphasis>4 integrin expression [<CitationRef CitationID="CR172_26">172</CitationRef>], increased E-cadherin expression [<CitationRef CitationID="CR177_26">177</CitationRef>], and inhibition of tenascin-C [<CitationRef CitationID="CR178_26">178</CitationRef>] may explain the anti-invasive activity of vitamin D.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Preclinical Studies of Calcitriol and Vitamin D Analogs in Combination with Other Antineoplastic Agents</Heading>
            <Section2 ID="Sec12">
              <Heading>Steroids</Heading>
              <Para TextBreak="No">The antineoplastic activity of vitamin D is enhanced by dexamethasone both in vitro and in vivo [<CitationRef CitationID="CR159_26">159</CitationRef>, <CitationRef CitationID="CR179_26">179</CitationRef>]. In SCC cells, dexamethasone increases both VDR protein levels and ligand binding [<CitationRef CitationID="CR179_26">179</CitationRef>]. Dexamethasone increases both vitamin D-induced cell cycle arrest and apoptosis. Phospho-Erk1/2 and phospho-Akt levels and tumor-derived endothelial cell growth are suppressed more completely by the combination than by vitamin D alone [<CitationRef CitationID="CR115_26">115</CitationRef>, <CitationRef CitationID="CR160_26">160</CitationRef>, <CitationRef CitationID="CR161_26">161</CitationRef>, <CitationRef CitationID="CR179_26">179</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec13">
              <Heading>Cytotoxic Chemotherapy</Heading>
              <Para TextBreak="No">Combinations of VDR ligands with several classes of chemotherapy drugs show additive or supra-additive activity in preclinical models. In prostate cancer models, enhanced activity of docetaxel [<CitationRef CitationID="CR180_26">180</CitationRef>], paclitaxel [<CitationRef CitationID="CR123_26">123</CitationRef>], platinum compounds [<CitationRef CitationID="CR181_26">181</CitationRef>], and mitoxantrone [<CitationRef CitationID="CR182_26">182</CitationRef>] has been reported. Animal model confirmation is available for paclitaxel and mitoxantrone [<CitationRef CitationID="CR123_26">123</CitationRef>, <CitationRef CitationID="CR182_26">182</CitationRef>]. Similar results have been reported in several other tumor types [<CitationRef CitationID="CR183_26">183</CitationRef>–<CitationRef CitationID="CR186_26">186</CitationRef>]; however, the mechanisms of these interactions remain incompletely understood.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec14">
            <Heading>Retinoid Receptor Ligands</Heading>
            <Para TextBreak="No">VDR forms heterodimers with RXR, thus synergistic growth inhibition by ligands for both receptors is expected [<CitationRef CitationID="CR187_26">187</CitationRef>, <CitationRef CitationID="CR188_26">188</CitationRef>]. Synergistic induction of apoptosis [<CitationRef CitationID="CR188_26">188</CitationRef>] and inhibition of angiogenesis for vitamin D–retinoid combinations have also been reported [<CitationRef CitationID="CR188_26">188</CitationRef>]. Common effects on IGFBP-3 may explain synergistic growth inhibition for the combination of RAR and VDR ligands [<CitationRef CitationID="CR189_26">189</CitationRef>]. Recently, the combination of 9-cis retinoic acid with calcitriol has been shown to inhibit the human telomerase reverse transcriptase in prostate cancer cells. This effect is not seen when either agent is tested alone [<CitationRef CitationID="CR190_26">190</CitationRef>]. Common activation of target genes, such as p21 may also underlie interactions between retinoids and vitamin D.</Para>
            <Section2 ID="Sec15">
              <Heading>Tamoxifen</Heading>
              <Para TextBreak="No">VDR ligands significantly increase the inhibition of ***<Emphasis Type="Italic">N</Emphasis>-nitroso-<Emphasis Type="Italic">N</Emphasis>-methylurea (NMU)-induced mammary carcinogenesis by tamoxifen in Sprague–Dawley rats [<CitationRef CitationID="CR191_26">191</CitationRef>]. Both in vitro and in vivo data using MCF-7 cells demonstrate enhanced apoptosis with the combination [<CitationRef CitationID="CR192_26">192</CitationRef>, <CitationRef CitationID="CR193_26">193</CitationRef>]. Interestingly, recent results in MCF-7 cells suggest that sensitivity to vitamin D varies inversely with sensitivity to antiestrogens suggesting that sequential or concurrent use of these compounds would be of significant interest [<CitationRef CitationID="CR194_26">194</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Nonsteroidal Anti-inflammatory Agents (NSAIDs)</Heading>
              <Para TextBreak="No">Simultaneous treatment of LNCaP cells with VDR ligands along with ibuprofen resulted in additive suppression of growth in the absence of dihydrotestosterone (DHT) and synergistic growth inhibition in under DHT-stimulated conditions. Both decreased G1-S transition and enhanced apoptosis ***were reported [<CitationRef CitationID="CR195_26">195</CitationRef>]. cDNA analysis of LNCaP cells treated with calcitriol showed that the expression of prostaglandin synthesizing COX-2 gene is significantly decreased by calcitriol, while the prostaglandin inactivating 15-prostaglandindehydrogenase gene was upregulated [<CitationRef CitationID="CR196_26">196</CitationRef>]. The combination of calcitriol and nonsteroidal anti-inflammatory agents (NSAIDs) synergistically acted to inhibit LNCaP cell growth [<CitationRef CitationID="CR197_26">197</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec17">
              <Heading>Radiation</Heading>
              <Para TextBreak="No">p21 expression, known to be induced by vitamin D in a number of tumor models, has also been shown to sensitize cells to radiation therapy [<CitationRef CitationID="CR198_26">198</CitationRef>]. Potentiation of radiation-induced apoptosis with VDR ligands has been shown in several tumor models [<CitationRef CitationID="CR199_26">199</CitationRef>, <CitationRef CitationID="CR200_26">200</CitationRef>] and in one analysis, increased ceramide generation may explain this interaction [<CitationRef CitationID="CR201_26">201</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec18">
            <Heading>Clinical Trials of Calcitriol and Vitamin D Analogs</Heading>
            <Para TextBreak="No">Calcitriol is clinically available and is indicated for patients who suffer from renal failure and therefore cannot adequately activate the storage form of vitamin D. The availability of this drug made it feasible for investigators to initiate studies in cancer. Because antineoplastic effects in vitro occur at significantly supraphysiologic concentrations (typically at or above 1 nM), dose escalation of calcitriol has been the goal of the phase I clinical programs.</Para>
          </Section1>
          <Section1 ID="Sec19">
            <Heading>Phase I Studies</Heading>
            <Para TextBreak="No">The first clinical trials in prostate cancer were designed to build on standard replacement dosing of calcitriol. Using a daily administration schedule, Osborn et al. sought to dose escalate calcitriol in 11 patients with castration-resistant prostate cancer (CRPC). No prostate-specific antigen (PSA) responses were seen at doses that ranged from 0.5 to 1.5 μg daily. Further dose escalation was not pursued due to the risk of hypercalcemia [<CitationRef CitationID="CR202_26">202</CitationRef>]. Gross et al. took a similar approach to the study of seven patients with a rising PSA that had not been treated with castrate-sensitive patients. No PSA responses were seen; however, treatment appeared to favorably impact PSA kinetics (the PSA doubling time was reduced when compared with the same prior to treatment). Hypercalciuria was cited as the reason for avoiding doses above 2.5 μg/day [<CitationRef CitationID="CR203_26">203</CitationRef>].</Para>
            <Section2 ID="Sec20">
              <Heading>Alternate Day Dosing</Heading>
              <Para TextBreak="No">Subcutaneous administration every other day was the approach designed to test two hypotheses: that both the route and schedule of administration may reduce the calcemic toxicity of calcitriol. While hypercalcemia was the dose-limiting toxicity, this approach allowed significant escalation of the dose, with 10 μg daily being the highest dose tested [<CitationRef CitationID="CR204_26">204</CitationRef>]. Peak blood calcitriol concentrations of approximately 0.7 nM were observed at the 8-μg dose.</Para>
            </Section2>
            <Section2 ID="Sec21">
              <Heading>Weekly Dosing</Heading>
              <Para TextBreak="No">In a dose-ranging study, weekly oral administration resulted in peak blood calcitriol concentrations of 3.7–6.0 nM without dose-limiting toxicity. Doses up to 2.8 μg/kg were examined; however, peak calcitriol concentrations (<Emphasis Type="Italic">C</Emphasis>
                <Subscript>max</Subscript>) and the area under the concentration curve (AUC) did not increase linearly at doses above 0.48 μg/kg [<CitationRef CitationID="CR205_26">205</CitationRef>]. This was the first study to report nonlinear pharmacokinetics with the commercially available formulation of calcitriol, a finding later confirmed by Muindi et al. [<CitationRef CitationID="CR206_26">206</CitationRef>]. This pharmacokinetic limitation, as well as the very large number of capsules required for treatment given the capsule sizes of 0.25 and 0.5 μg, later led to the development of a new high-dose formulation of calcitriol, DN-101. Administered as a single dose, DN-101 exhibits a dose-proportional increase in both <Emphasis Type="Italic">C</Emphasis>
                <Subscript>max</Subscript> and AUC across a broad range of doses (15–165 μg). As a result, peak calcitriol concentrations achieved in this study were higher than in any previously reported study(14.9 nM at the 165-μg dose) [<CitationRef CitationID="CR207_26">207</CitationRef>]. In the preliminary report of the results with weekly dosing, grade 2 self-limited hypercalcemia was seen with repeat weekly dosing at 60 μg. Consequently, 45 μg weekly was recommended as the phase II weekly dose [<CitationRef CitationID="CR208_26">208</CitationRef>]. It is likely, however, that additional dose escalation on the weekly schedule would be feasible if either more conventional criteria for dose-limiting toxicity had been applied (grade 3 rather than grade 2 hypercalcemia) or if DN-101 were coadministered with an agent capable of reducing hypercalcemia.</Para>
            </Section2>
            <Section2 ID="Sec22">
              <Heading>Dosing 3 of Every 7 Days</Heading>
              <Para TextBreak="No">Another approach to weekly dosing was administration of calcitriol for three consecutive days repeated every 7 days. In a phase I trial that combined calcitriol on this schedule with paclitaxel, daily doses up to 38 μg on three consecutive days every 7 days were administered without dose-limiting toxicity and produced a ***<Emphasis Type="Italic">C</Emphasis>max that ranged from 1.4 to 3.5 nM at the highest doses [<CitationRef CitationID="CR207_26">207</CitationRef>]. The same schedule of calcitriol was also evaluated in combination with zoledronate with dexamethasone added upon progression [<CitationRef CitationID="CR209_26">209</CitationRef>]. Daily calcitriol doses up to 30 μg for three consecutive days every 7 days were administered without dose-limiting toxicity and three patients had calcitriol dose reductions due to related laboratory abnormalities. There were no responses to calcitriol and zoledronate and one of seven patients responded when dexamethasone was added upon progression of the initial regimen.</Para>
            </Section2>
            <Section2 ID="Sec23">
              <Heading>Dosing Every 3 Weeks</Heading>
              <Para TextBreak="No">If calcitriol is primarily used to modify tumor response to chemotherapy, even less frequent dosing may be useful, particularly when the chemotherapy regimen is dosed infrequently. Tiffany et al. tested 60 μg of calcitriol every 3 weeks 24 h before chemotherapy with docetaxel and estramustine [<CitationRef CitationID="CR210_26">210</CitationRef>]. The study used a dose de-escalation design and demonstrated that 60 μg can be safely administered on this schedule. Fifty-five percent of chemotherapy-naïve and 9% of patients previously treated with docetaxel-containing chemotherapy responded, but the study was not powered to show response.</Para>
              <Para TextBreak="No">The phase 1 efforts of a number of investigators clearly demonstrate that significant dose escalation of calcitriol with intermittent dosing is feasible. Indeed, most studies did not identify a maximum tolerated dose as dose escalation was limited by the number of capsules needed and by the nonlinear pharmacokinetics of the commercially available formulation of calcitriol. The DN-101 formulation overcomes both of these limitations and has been now studied the most extensively.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec24">
            <Heading>Phase II Studies</Heading>
            <Section2 ID="Sec25">
              <Heading>Single Agent Calcitriol</Heading>
              <Para TextBreak="No">Weekly calcitriol has been tested as a single agent in castrate-sensitive prostate cancer and in combination with docetaxel in CRPC. In a nonrandomized study carried out in patients who had a biochemical progression after prostatectomy or radiation therapy, weekly calcitriol administered at a dose of 0.5 μg/kg was administered safely for a median of 10 months [<CitationRef CitationID="CR211_26">211</CitationRef>]. There were no confirmed PSA reductions in excess of 50%, but lesser PSA reductions as well as lengthening of the PSA doubling time when compared with pretreatment conditions were observed.</Para>
              <Para TextBreak="No">Trump et al. performed another trial of calcitriol as a primary therapy for CRPC [<CitationRef CitationID="CR212_26">212</CitationRef>]. Calcitriol was administered orally on a weekly basis every Monday, Tuesday, and Wednesday (MTW) at a dosage of 8 μg for 4 weeks, 10 μg for the subsequent 4 weeks, and at 12 μg thereafter. Dexamethasone was administered orally each Sunday and MTW weekly at a dosage of 4 mg. Eight (19%) of 43 patients experienced a biochemical response (≥50%; median decrease, 64%; range, 55–92%) persisting for ≥28 days. One patient experienced a decrease in PSA levels by 73%. However, persistent PSA decline was not assessed as the patient died 6 weeks after commencement of treatment due to a pulmonary embolism believed to be unrelated to treatment. Only four patients had a serum calcium level of &gt;11.0 mg/dL. The biochemical response rate was similar to that of dexamethasone alone, but the regimen was well tolerated.</Para>
              <Para TextBreak="No">While these findings are suggestive of antitumor activity, a randomized trial would be needed to determine their clinical significance.</Para>
            </Section2>
            <Section2 ID="Sec26">
              <Heading>Combination with Docetaxel</Heading>
              <Para TextBreak="No">These encouraging results led to the development of ASCENT (AIPC Study of Calcitriol Enhancing Taxotere), a placebo-controlled multi-institutional randomized study that randomized patients to weekly docetaxel (36 mg/m<Superscript>2</Superscript>) with DN-101 45 μg or placebo [<CitationRef CitationID="CR213_26">213</CitationRef>, <CitationRef CitationID="CR214_26">214</CitationRef>]. A total of 250 US and Canadian patients were entered. DN-101 was administered 24 h before docetaxel. This regimen was administered weekly for three consecutive weeks and repeated every 4 weeks. The primary end point of this study is a comparison of PSA response of &gt;50% in the two arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (<Emphasis Type="Italic">P</Emphasis>= 0.16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), <Emphasis Type="Italic">P</Emphasis>= 0.07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (<Emphasis Type="Italic">P</Emphasis>= 0.04) in a multivariate analysis that included baseline hemoglobin and performance status. Beer et al. noted that median survival had not been reached in the DN-101 arm but estimated a median survival of 24.5 months compared with 16.4 months in the placebo arm. As the primary endpoint of this study was PSA response rate and not overall survival, a definitive phase III study (ASCENT-2) powered to evaluate survival was launched in 2006 and was closed to accrual in November 2007 with more than 900 of the intended 1,200 patients. Results from this trial are not yet publicly available. Because of advances in the field of chemotherapy for prostate cancer this study compared docetaxel administered weekly once with DN-101 to docetaxel administered every 3 weeks without DN-101. The trial was closed early by the DSMB due to an imbalance in the deaths.</Para>
              <Para TextBreak="No">An alternative calcitriol agent was reported in a phase II study by Attia et al. [<CitationRef CitationID="CR215_26">215</CitationRef>]. Patients with CRPC were randomized to receive docetaxel 35 mg/m<Superscript>2</Superscript> IV on days 1, 8, and 15 of a 28-day cycle either with or without doxercalciferol (1a-dihydroxyvitamin D2, Hectorol, Genzyme). This is an inactive prohormone that is hepatically metabolized and activated to 1<Emphasis Type="Italic">α</Emphasis>,25-dihydroxyvitamin D2 and 1<Emphasis Type="Italic">α</Emphasis>,24-dihydroxyvitamin D2 [<CitationRef CitationID="CR216_26">216</CitationRef>]. This agent has the advantage of less hypercalcemia as supported by early clinical studies [<CitationRef CitationID="CR217_26">217</CitationRef>]. Doxercalciferol was given at 10 μg orally, daily for 28 days. Seventy patients were randomized. PSA responses favored the doxercalciferol arm but did not meet statistical significance (46.7% vs. 39.5%, <Emphasis Type="Italic">P</Emphasis> = 0.560). Median progression-free survival also did not differ significantly (6.17 months vs. 6.20 months, <Emphasis Type="Italic">P</Emphasis>= 0.764).</Para>
            </Section2>
            <Section2 ID="Sec27">
              <Heading>Combinations with Carboplatin</Heading>
              <Para TextBreak="No">A small phase II study also examined calcitriol 0.5 μg/kg in combination with carboplatin at an AUC dose of 7 (six in patients with prior radiation) dosed every 4 weeks [<CitationRef CitationID="CR218_26">218</CitationRef>]. The response rate was less than 10% and toxicity was unremarkable. It is not clear if this less encouraging result is related to the infrequent dosing schedule of calcitriol, to platinum resistance of prostate cancer, or due to chance given the small sample size (<Emphasis Type="Italic">n</Emphasis> = 17).</Para>
              <Para TextBreak="No">A second phase II study was conducted with carboplatin, dexamethasone, and calcitriol by Flaig et al. [<CitationRef CitationID="CR219_26">219</CitationRef>]. In this study, men with CRPC were started on dexamethasone 1 mg daily. After 5 weeks, they were also given 0.5 μg of calcitriol provided their calcium remained &lt;10.1 mg/dL. After 2 weeks of the additional calcitriol, carboplatin (AUC=2) administered weekly was begun. The regimen was not well tolerated by the initial group; thus, carboplatin dosing was changed to 4 weekly doses with 2 weeks of rest. Of the 34 patients treated, 13 showed PSA response. Of note, two patients died of cardiac complications and four experienced grade 3 neutropenia.</Para>
            </Section2>
            <Section2 ID="Sec28">
              <Heading>Combination with Mitoxantrone</Heading>
              <Para TextBreak="No">Chan et al. have also tested the safety and efficacy of DN-101 with mitoxantrone [<CitationRef CitationID="CR220_26">220</CitationRef>]. DN-101 was given at a dose of 180 μg 24 h prior to mitoxantrone 12 mg/m<Superscript>2</Superscript> every 21 days with continuous oral prednisone for a maximum of 12 cycles. Five of 19 patients (26%; 95% confidence interval, CI, 9–51) achieved a ≥50% decline in PSA level. The median (95% CI) time to PSA progression was 16 (6–26) weeks. The overall median (95% CI) survival was 16 (6–26) months; 47 (21–73%) of patients achieved an analgesic response. Toxicity was similar to that expected with mitoxantrone and prednisone alone. The quality of life analysis suggested a decrease in physical functioning and increase in fatigue, insomnia, and diarrhea. The regimen is usable but will need to be evaluated further to determine if and when it should be employed in relationship to docetaxel-based chemotherapy.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec29">
            <Heading>Other Calcitriol Analogs</Heading>
            <Para TextBreak="No">While much of the clinical testing of VDR ligands has been conducted with calcitriol, the naturally occurring ligand, another approach has been to develop calcitriol analogs designed to decouple antineoplastic activity from calcemic toxicity. The most common synthetic approach has been to modify the side chain of the calcitriol molecule and many such compounds have been chemically synthesized. Differences in protein binding, VDR affinity, and drug metabolism have all been cited as explanation for reduced calcemic activity [<CitationRef CitationID="CR221_26">221</CitationRef>–<CitationRef CitationID="CR223_26">223</CitationRef>]. Several of these compounds have entered clinical trials, some in prostate cancer. After phase I evaluation [<CitationRef CitationID="CR224_26">224</CitationRef>], Seocalcitol (EB1089) 10 μg daily was evaluated in phase II studies in pancreatic and hepatocellular carcinoma. No objective responses were seen in patients with pancreatic cancer [<CitationRef CitationID="CR225_26">225</CitationRef>], but two of 33 evaluable patients with unresectable hepatocellular carcinoma achieved complete remission that had endured beyond 29 months (last point of analysis) [<CitationRef CitationID="CR226_26">226</CitationRef>]. Three of the 14 patients with locally advanced or cutaneous metastatic adenocarcinoma of the breast responded to topical calcipotriol [<CitationRef CitationID="CR227_26">227</CitationRef>]. Two of 25 CRPC patients had objective partial responses in a phase I trial of 1-alphahydroxyvitamin D2 [<CitationRef CitationID="CR228_26">228</CitationRef>]. This study identified 12.5 μg as the phase II dose after encountering dose-limiting hypercalcemia and renal insufficiency. A follow-up phase II study examined this regimen in 26 patients with androgen-independent prostate cancer. As the investigators expected this analog to act primarily as a cytostatic agent, the trial’s primary endpoint was progression-free survival. Median time to progression was 12 weeks (mean 19 weeks) and one patient had stable disease for &gt;2 years. The vitamin D3 analog ILX23-7553 has entered phase I clinical trials and was safe at doses up to 45 μg/m<Superscript>2</Superscript>/day for five consecutive days repeated every 14 days. The study was discontinued before dose-limiting toxicity was identified due to the number of capsules required. The authors suggest that further dose escalation should be pursued using a reformulated higher dose capsule [<CitationRef CitationID="CR229_26">229</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec30" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">There are intriguing epidemiological data and strong preclinical data that support targeting the VDR for cancer therapy in general and prostate cancer therapy, specifically. Most of the clinical trials conducted to date have examined supplementation with calcitriol, the naturally occurring ligand of the vitamin D receptor. Significant dose escalation of this compound is not feasible when it is dosed daily due to predictable hypercalcemia. Various intermittent dosing approaches have been developed and all demonstrate that intermittent dosing allows substantial escalation of the calcitriol dose and consequently of calcitriol exposure. An alternative approach is the development of calcitriol analogs that seek to uncouple antineoplastic activity from calcemic action. Several such analogs have entered clinical trials, but in prostate cancer have been less extensively studied than calcitriol. Single agent studies have largely focused on safety. Confirmed responses to single agent calcitriol or its analogs have been rarely reported. Stabilization of disease or apparent slowing of the rate of rise in serum PSA has been more often seen. While disease stabilization or PSA slowing are findings that are consistent with the hypothesis that VDR ligands are acting as cytostatic agents, the available studies are small and uncontrolled and are not sufficient to draw firm conclusions about the clinical meaning of these observations. Progress in single agent VDR ligand therapy will require a commitment to larger, randomized prospective clinical trials. A better understanding of the molecular determinants of response and resistance to calcitriol would also be helpful as it could allow for better selection of patients whose tumors are vulnerable to this class of agents. To date, phase I and II clinical data with calcitriol and other vitamin D analogs support its safety in concert with cytotoxic therapy. Impact on efficacy of therapy needs further testing at this time. Of these agents only DN-101 has reached phase III clinical testing. Despite the early closure of ASCENT-2, the final results may provide additional insight as to what role manipulation of vitamin D-oriented therapeutics may have in prostate cancer treatment.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_26.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_26">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Hanchette</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>70</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2861</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>1451068</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2Fot1Khtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70(12):2861–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_26">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Luscombe</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1504</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11720436</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XkslemsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Luscombe CJ, et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001;85(10):1504–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_26">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Grant</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>94</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1867</FirstPage>
                <LastPage>75</LastPage>
                <Occurrence Type="PID">
                  <Handle>11920550</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94(6):1867–75.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_26">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Corder</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Vitamin D and prostate cancer: a prediagnostic study with stored sera</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>467</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>8220092</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c%2FjsVOhuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Corder EH, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2(5):467–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_26">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Gann</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Circulating vitamin D metabolites in relation to subsequent development of prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>121</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8850273</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s%2Fgt12gtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gann PH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5(2):121–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_26">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Jacobs</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>89–90</VolumeID>
                <IssueID>1–5</IssueID>
                <FirstPage>533</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15225833</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jacobs ET, et al. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89–90(1–5):533–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_26">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Nomura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>425</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>9794175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M%2FgvVaktQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nomura AM, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9(4):425–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_26">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Platz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>255</FirstPage>
                <LastPage>65</LastPage>
                <Occurrence Type="PID">
                  <Handle>15090720</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Platz EA, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15(3):255–65.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_26">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Ahonen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>847</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>11075874</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M3osVeqtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ahonen MH, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11(9):847–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_26">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Tuohimaa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>108</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>104</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>14618623</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXps1entbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tuohimaa P, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108(1):104–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_26">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>559</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>10189041</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3gt12htg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chan JM, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998;9(6):559–66.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_26">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland)</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>859</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>11075876</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M3osVeqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chan JM, et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000;11(9):859–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_26">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Calcium and fructose intake in relation to risk of prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>442</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9458087</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnsFeisw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giovannucci E, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998;58(3):442–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_26">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Kristal</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Associations of energy, fat, calcium, and vitamin D with prostate cancer risk</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>719</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>12163324</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XmvVaqsL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kristal AR, et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11(8):719–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_26">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Park</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study</ArticleTitle>
                <JournalTitle>Am J Epidemiol</JournalTitle>
                <VolumeID>166</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1259</FirstPage>
                <LastPage>69</LastPage>
                <Occurrence Type="PID">
                  <Handle>17925283</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Park SY, et al. Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007;166(11):1259–69.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_26">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Huncharek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Muscat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Kupelnick</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies</ArticleTitle>
                <JournalTitle>Nutr Cancer</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>421</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>18584476</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 2008;60(4):421–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_26">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LQ</Initials>
                  <FamilyName>Qin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Milk consumption is a risk factor for prostate cancer: meta-analysis of case-control studies</ArticleTitle>
                <JournalTitle>Nutr Cancer</JournalTitle>
                <VolumeID>48</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>22</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15203374</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Qin LQ, et al. Milk consumption is a risk factor for prostate cancer: meta-analysis of case-control studies. Nutr Cancer 2004;48(1):22–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_26">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HS</Initials>
                  <FamilyName>Cross</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis</ArticleTitle>
                <JournalTitle>Steroids</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>3–5</IssueID>
                <FirstPage>287</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>11179736</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXhtFehtrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cross HS, et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001;66(3–5):287–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_26">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Tangpricha</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>357</VolumeID>
                <IssueID>9269</IssueID>
                <FirstPage>1673</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>11425375</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXks1Knu70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tangpricha V, et al. 25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001;357(9269):1673–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_26">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>315</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>12520532</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXntlyktw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen TC, et al. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003;88(2):315–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_26">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JY</Initials>
                  <FamilyName>Hsu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2852</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11306457</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXivFGru78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsu JY, et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001;61(7):2852–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_26">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Bouillon</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1987</Year>
                <ArticleTitle Language="En">Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency</ArticleTitle>
                <JournalTitle>Am J Clin Nutr</JournalTitle>
                <VolumeID>45</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>755</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>3494392</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXkt1agtrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bouillon RA, et al. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr 1987;45(4):755–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_26">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Dandona</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1986</Year>
                <ArticleTitle Language="En">Low 1,25-dihydroxyvitamin D, secondary hyperparathyroidism, and normal osteocalcin in elderly subjects</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>459</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>3487550</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL283ltFWqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dandona P, et al. Low 1,25-dihydroxyvitamin D, secondary hyperparathyroidism, and normal osteocalcin in elderly subjects. J Clin Endocrinol Metab 1986;63(2):459–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_26">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dubbelman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Age-dependent vitamin D status and vertebral condition of white women living in Curacao (The Netherlands Antilles) as compared with their counterparts in The Netherlands</ArticleTitle>
                <JournalTitle>Am J Clin Nutr</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>106</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8317380</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szgsVaqsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dubbelman R, et al. Age-dependent vitamin D status and vertebral condition of white women living in Curacao (The Netherlands Antilles) as compared with their counterparts in The Netherlands. Am J Clin Nutr 1993;58(1):106–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_26">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lips</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial</ArticleTitle>
                <JournalTitle>Ann Intern Med</JournalTitle>
                <VolumeID>124</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>400</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8554248</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK287ltF2nsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lips P, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124(4):400–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_26">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>567</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>10189042</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3gt12htw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998;9(6):567–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_26">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2225</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>15598784</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVOjsLnJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2004;13(12):2225–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_26">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Kidd</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Sequence variation within the 5′ regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>272</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>15717311</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXotFSmtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kidd LC, et al. Sequence variation within the 5′ regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate 2005;64(3):272–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_26">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KC</Initials>
                  <FamilyName>Torkko</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>3223</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18483391</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmtVCmu70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Torkko KC, et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 2008;14(10):3223–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_26">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2303</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16214909</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVymt7rE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhou W, et al. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14(10):2303–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_26">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TE</Initials>
                  <FamilyName>Robsahm</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway)</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>149</FirstPage>
                <LastPage>58</LastPage>
                <Occurrence Type="PID">
                  <Handle>15017127</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Robsahm TE, et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004;15(2):149–58.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_26">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Lagunova</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Prostate cancer survival is dependent on season of diagnosis</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>1362</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>17624920</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lagunova Z, et al. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007;67(12):1362–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_26">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Mangelsdorf</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">The nuclear receptor superfamily: the second decade</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>83</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>835</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8521507</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXhtVSnu7nJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mangelsdorf DJ, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83(6):835–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_26">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Carlberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Saurat</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Vitamin D-retinoid association: molecular basis and clinical applications</ArticleTitle>
                <JournalTitle>J Investig Dermatol Symp Proc</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>82</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9627699</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xkt1emtrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carlberg C, Saurat JH. Vitamin D-retinoid association: molecular basis and clinical applications. J Investig Dermatol Symp Proc 1996;1(1):82–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_26">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Conde</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Expression of vitamin D3 receptor and retinoid receptors in human breast cancer: identification of potential heterodimeric receptors</ArticleTitle>
                <JournalTitle>Int J Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1183</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>15375571</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXovFWktLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Conde I, et al. Expression of vitamin D3 receptor and retinoid receptors in human breast cancer: identification of potential heterodimeric receptors. Int J Oncol 2004;25(4):1183–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_26">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Kliewer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>355</VolumeID>
                <IssueID>6359</IssueID>
                <FirstPage>446</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>1310351</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XhtVSisLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kliewer SA, et al. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992;355(6359):446–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_26">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Nanes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">A single up-stream element confers responsiveness to 1,25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>134</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1113</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>8119149</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXis1aqsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nanes MS, et al. A single up-stream element confers responsiveness to 1,25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene. Endocrinology 1994;134(3):1113–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_26">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Koszewski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Reinhardt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Horst</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Vitamin D receptor interactions with the murine osteopontin response element</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>5–6</IssueID>
                <FirstPage>377</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>9010343</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhtVGntb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Koszewski NJ, Reinhardt TA, Horst RL. Vitamin D receptor interactions with the murine osteopontin response element. J Steroid Biochem Mol Biol 1996;59(5–6):377–88.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_26">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene</ArticleTitle>
                <JournalTitle>Biochem J</JournalTitle>
                <VolumeID>318</VolumeID>
                <IssueID>Pt 1</IssueID>
                <FirstPage>219</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>8761475</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kim RH, et al. Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Biochem J 1996;318(Pt 1):219–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_26">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kitazawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kitazawa</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>290</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>650</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>11785948</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xislamug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kitazawa R, Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 2002;290(2):650–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_26">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Drissi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter</ArticleTitle>
                <JournalTitle>Exp Cell Res</JournalTitle>
                <VolumeID>274</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>323</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>11900492</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XitVaisrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drissi H, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002;274(2):323–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_26">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Hakim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Bar-Shavit</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>986</FirstPage>
                <LastPage>98</LastPage>
                <Occurrence Type="PID">
                  <Handle>12616536</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXisVKktbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hakim I, Bar-Shavit Z. Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem 2003;88(5):986–98.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_26">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NS</Initials>
                  <FamilyName>Hawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>O’Riordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Farrow</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>228</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>352</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8920918</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmvVOmtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hawa NS, O’Riordan JL, Farrow SM. Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene. Biochem Biophys Res Commun 1996;228(2):352–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_26">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Falzon</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">DNA sequences in the rat parathyroid hormone-related peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>672</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>8776727</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjsVSqs7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Falzon M. DNA sequences in the rat parathyroid hormone-related peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression. Mol Endocrinol 1996;10(6):672–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_26">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Maestro</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Identification of a vitamin D response element in the human insulin receptor gene promoter</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>84</VolumeID>
                <IssueID>2–3</IssueID>
                <FirstPage>223</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>12711007</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjtFWgsrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maestro B, et al. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003;84(2–3):223–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_26">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>399</FirstPage>
                <LastPage>408</LastPage>
                <Occurrence Type="PID">
                  <Handle>15528275</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhsVCmt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee S, et al. Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol Endocrinol 2005;19(2):399–408.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_26">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Quelo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Machuca</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Jurdic</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Identification of a vitamin D response element in the proximal promoter of the chicken carbonic anhydrase II gene</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>273</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>10638</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>9553126</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXivFKnu7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Quelo I, Machuca I, Jurdic P. Identification of a vitamin D response element in the proximal promoter of the chicken carbonic anhydrase II gene. J Biol Chem 1998;273(17):10638–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_26">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Seoane</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Localization of a negative vitamin D response sequence in the human growth hormone gene</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>292</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>250</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>11890700</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xhslygsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Seoane S, et al. Localization of a negative vitamin D response sequence in the human growth hormone gene. Biochem Biophys Res Commun 2002;292(1):250–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_26">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Gill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Christakos</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2984</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8464915</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXisV2hsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gill RK, Christakos S. Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl Acad Sci U S A 1993;90(7):2984–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_26">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Fujisawa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Identification of a response element for vitamin D3 and retinoic acid in the promoter region of the human fructose-1,6-bisphosphatase gene</ArticleTitle>
                <JournalTitle>J Biochem</JournalTitle>
                <VolumeID>127</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>373</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>10731708</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjtlGqur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fujisawa K, et al. Identification of a response element for vitamin D3 and retinoic acid in the promoter region of the human fructose-1,6-bisphosphatase gene. J Biochem 2000;127(3):373–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_26">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937</ArticleTitle>
                <JournalTitle>Genes Dev</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>142</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>8566748</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XotlKnsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liu M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10(2):142–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_26">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>278</VolumeID>
                <IssueID>48</IssueID>
                <FirstPage>48030</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>14506229</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpt1Gjs7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jiang F, et al. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 2003;278(48):48030–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_26">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Matilainen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>Nucleic Acids Res</JournalTitle>
                <VolumeID>33</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>5521</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>16186133</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFWltrvK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matilainen M, et al. Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res 2005;33(17):5521–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_26">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Peng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Malloy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1109</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>14963110</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjvVOktro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004;18(5):1109–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_26">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Zierold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Darwish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>DeLuca</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>91</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>900</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="PID">
                  <Handle>8302863</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhvVCgtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zierold C, Darwish HM, DeLuca HF. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc Natl Acad Sci U S A 1994;91(3):900–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_26">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PD</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>299</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>730</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12470639</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xps1Wiurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson PD, et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 2002;299(5):730–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_26">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>McCarthy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Sinal</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>280</VolumeID>
                <IssueID>24</IssueID>
                <FirstPage>23232</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>15824121</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltVyhu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McCarthy TC, Li X, Sinal CJ. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 2005;280(24):23232–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_26">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>McGaffin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Chrysogelos</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells</ArticleTitle>
                <JournalTitle>J Mol Endocrinol</JournalTitle>
                <VolumeID>35</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>117</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>16087726</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslOhtbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McGaffin KR, Chrysogelos SA. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol 2005;35(1):117–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_26">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Candeliere</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c-fos promoter</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>584</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>8552086</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmtVWhsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Candeliere GA, et al. A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c-fos promoter. Mol Cell Biol 1996;16(2):584–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_26">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Xie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Bikle</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Differential regulation of vitamin D responsive elements in normal and transformed keratinocytes</ArticleTitle>
                <JournalTitle>J Invest Dermatol</JournalTitle>
                <VolumeID>110</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>730</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>9579536</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjtVGntrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xie Z, Bikle DD. Differential regulation of vitamin D responsive elements in normal and transformed keratinocytes. J Invest Dermatol 1998;110(5):730–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_26">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Polly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>322</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>8867808</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhvVGitrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Polly P, et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem 1996;60(3):322–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_26">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Cao</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>268</VolumeID>
                <IssueID>36</IssueID>
                <FirstPage>27371</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>8262978</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhsFGhtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cao X, et al. Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. J Biol Chem 1993;268(36):27371–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_26">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Bikle</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">The vitamin D response element of the involucrin gene mediates its regulation by 1,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>J Invest Dermatol</JournalTitle>
                <VolumeID>119</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1109</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>12445200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XpslCrtL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bikle DD, et al. The vitamin D response element of the involucrin gene mediates its regulation by 1,25-dihydroxyvitamin D3. J Invest Dermatol 2002;119(5):1109–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_26">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Deftos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Direct evidence that PTHrP expression promotes prostate cancer progression in bone</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>327</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>468</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>15629138</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXksF2j</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Deftos LJ, et al. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005;327(2):468–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_26">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Lynch</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>485</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>15894268</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXkslyitLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lynch CC, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7(5):485–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_26">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Tenta</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells</ArticleTitle>
                <JournalTitle>Horm Metab Res</JournalTitle>
                <VolumeID>37</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>593</FirstPage>
                <LastPage>601</LastPage>
                <Occurrence Type="PID">
                  <Handle>16278781</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht1Wrur%2FF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tenta R, et al. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res 2005;37(10):593–601.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_26">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Nemere</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Yoshimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>115</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1476</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>6548181</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXlvFSiurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nemere I, Yoshimoto Y, Norman AW. Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D3. Endocrinology 1984;115(4):1476–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_26">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Boland</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Boland</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Non-genomic signal transduction pathway of vitamin D in muscle</ArticleTitle>
                <JournalTitle>Cell Signal</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>717</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>7888298</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal 1994;6(7):717–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_26">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Edelman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garabedian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Anagnostopoulos</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Mechanisms of 1,25(OH)2D3-induced rapid changes of membrane potential in proximal tubule: role of Ca2+-dependent K+ channels</ArticleTitle>
                <JournalTitle>J Membr Biol</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>137</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>2425094</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XktVSku7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Edelman A, Garabedian M, Anagnostopoulos T. Mechanisms of 1,25(OH)2D3-induced rapid changes of membrane potential in proximal tubule: role of Ca2+-dependent K+ channels. J Membr Biol 1986;90(2):137–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_26">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Beno</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>270</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3642</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>7876102</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXjvVyrs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beno DW, et al. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction. J Biol Chem 1995;270(8):3642–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_26">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Boland</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Age-associated decrease in inositol 1,4,5-trisphosphate and diacylglycerol generation by 1,25(OH)2-vitamin D3 in rat intestine</ArticleTitle>
                <JournalTitle>Cell Signal</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>153</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8736697</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Boland AR, et al. Age-associated decrease in inositol 1,4,5-trisphosphate and diacylglycerol generation by 1,25(OH)2-vitamin D3 in rat intestine. Cell Signal 1996;8(3):153–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_26">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Boland</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Morelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Boland</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">1,25(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>269</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>8675</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8132595</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Boland AR, Morelli S, Boland R. 1,25(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J Biol Chem 1994;269(12):8675–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_26">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Capiati</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>93</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>384</FirstPage>
                <LastPage>97</LastPage>
                <Occurrence Type="PID">
                  <Handle>15368364</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXotVyiu78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Capiati DA, et al. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells. J Cell Biochem 2004;93(2):384–97.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_26">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gniadecki</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes</ArticleTitle>
                <JournalTitle>J Invest Dermatol</JournalTitle>
                <VolumeID>106</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1212</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8752659</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XksVajsLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gniadecki R. Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes. J Invest Dermatol 1996;106(6):1212–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_26">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WH</Initials>
                  <FamilyName>Park</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase</ArticleTitle>
                <JournalTitle>Br J Haematol</JournalTitle>
                <VolumeID>109</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>576</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>10886207</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkvVWktL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Park WH, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000;109(3):576–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_26">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Rossi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">MAPK inhibition by 1alpha,25(OH)2-vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>89–90</VolumeID>
                <IssueID>1–5</IssueID>
                <FirstPage>287</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>15225787</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rossi AM, et al. MAPK inhibition by 1alpha,25(OH)2-vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src. J Steroid Biochem Mol Biol 2004;89–90(1–5):287–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_26">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bellido</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Evidence for the participation of protein kinase C and 3′,5′-cyclic AMP-dependent protein kinase in the stimulation of muscle cell proliferation by 1,25-dihydroxy-vitamin D3</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>231</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>7684342</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXnsVentw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bellido T, et al. Evidence for the participation of protein kinase C and 3′,5′-cyclic AMP-dependent protein kinase in the stimulation of muscle cell proliferation by 1,25-dihydroxy-vitamin D3. Mol Cell Endocrinol 1993;90(2):231–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_26">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Vazquez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Boland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Boland</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts</ArticleTitle>
                <JournalTitle>Biochim Biophys Acta</JournalTitle>
                <VolumeID>1269</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>91</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>7578277</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vazquez G, Boland R, de Boland AR. Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts. Biochim Biophys Acta 1995;1269(1):91–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_26">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Massheimer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Boland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Boland</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Rapid 1,25(OH)2-vitamin D3 stimulation of calcium uptake by rat intestinal cells involves a dihydropyridine-sensitive cAMP-dependent pathway</ArticleTitle>
                <JournalTitle>Cell Signal</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>299</FirstPage>
                <LastPage>304</LastPage>
                <Occurrence Type="PID">
                  <Handle>7917787</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlsV2ksL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Massheimer V, Boland R, de Boland AR. Rapid 1,25(OH)2-vitamin D3 stimulation of calcium uptake by rat intestinal cells involves a dihydropyridine-sensitive cAMP-dependent pathway. Cell Signal 1994;6(3):299–304.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_26">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Santillan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Boland</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Studies suggesting the participation of protein kinase A in 1,25(OH)2-vitamin D3-dependent protein phosphorylation in cardiac muscle</ArticleTitle>
                <JournalTitle>J Mol Cell Cardiol</JournalTitle>
                <VolumeID>30</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>225</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>9514999</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXit1Cjt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Santillan GE, Boland RL. Studies suggesting the participation of protein kinase A in 1,25(OH)2-vitamin D3-dependent protein phosphorylation in cardiac muscle. J Mol Cell Cardiol 1998;30(2):225–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_26">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Hmama</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>190</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1583</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>10587349</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXnvF2nsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hmama Z, et al. 1Alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med 1999;190(11):1583–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_26">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA. Silencing of the p110alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>9379</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>14672955</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhs1Omsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee JS, et al. Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA. Silencing of the p110alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide. J Biol Chem 2004;279(10):9379–88.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_26">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bektas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Orfanos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Geilen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT</ArticleTitle>
                <JournalTitle>Cell Mol Biol (Noisy-le-grand)</JournalTitle>
                <VolumeID>46</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>111</FirstPage>
                <LastPage>9</LastPage>
              </BibArticle>
              <BibUnstructured>Bektas M, Orfanos CE, Geilen CC, et al. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol (Noisy-le-grand) 2004;46(1):111–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_26">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Rebsamen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase</ArticleTitle>
                <JournalTitle>Circ Res</JournalTitle>
                <VolumeID>91</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>17</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>12114317</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFKksLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rebsamen MC, et al. 1Alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91(1):17–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_26">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D(3) and 24R, 25-dihydroxyvitamin D(3) modulate growth plate chondrocyte physiology via protein kinase C-dependent phosphorylation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>143</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2775</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>12072413</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XltVymt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schwartz Z, et al. 1Alpha,25-dihydroxyvitamin D(3) and 24R, 25-dihydroxyvitamin D(3) modulate growth plate chondrocyte physiology via protein kinase C-dependent phosphorylation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase. Endocrinology 2002;143(7):2775–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_26">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Erben</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1524</FirstPage>
                <LastPage>37</LastPage>
                <Occurrence Type="PID">
                  <Handle>12089348</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsVGitbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Erben RG, et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 2002;16(7):1524–37.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_26">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Huhtakangas</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2660</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>15272054</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpslKksrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huhtakangas JA, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 2004;18(11):2660–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_26">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MT</Initials>
                  <FamilyName>Mizwicki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Evidence that annexin II is not a putative membrane receptor for 1alpha,25(OH)2-vitamin D3</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>91</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>852</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>14991775</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXitlGisbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mizwicki MT, et al. Evidence that annexin II is not a putative membrane receptor for 1alpha,25(OH)2-vitamin D3. J Cell Biochem 2004;91(4):852–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_26">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R, 25(OH)2-vitamin D3</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>197</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>1</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>12431790</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosFCmsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Norman AW, et al. Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R, 25(OH)2-vitamin D3. Mol Cell Endocrinol 2002;197(1–2):1–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_26">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1alpha,25-dihydroxyvitamin D3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1518</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>9280067</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXlsF2mtL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Norman AW, et al. Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1alpha,25-dihydroxyvitamin D3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses. Mol Endocrinol 1997;11(10):1518–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_26">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Rohe</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS)-binding protein in rat IEC-6 cells</ArticleTitle>
                <JournalTitle>Steroids</JournalTitle>
                <VolumeID>70</VolumeID>
                <IssueID>5–7</IssueID>
                <FirstPage>458</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>15862831</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjvVOitb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rohe B, et al. Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS)-binding protein in rat IEC-6 cells. Steroids 2005;70(5–7):458–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_26">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Abe</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1981</Year>
                <ArticleTitle Language="En">Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>78</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>4990</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>6946446</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3MXlvFOqsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Abe E, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981;78(8):4990–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_26">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Konety</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>165</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>253</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11125420</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXhtFOgug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Konety BR, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001;165(1):253–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_26">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Colston</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>44</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>693</FirstPage>
                <LastPage>702</LastPage>
                <Occurrence Type="PID">
                  <Handle>1324683</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xls1enur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Colston KW, et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992;44(4):693–702.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_26">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HS</Initials>
                  <FamilyName>Cross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Huber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Peterlik</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>179</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>57</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>1883380</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXmt1Clt7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cross HS, Huber C, Peterlik M. Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium. Biochem Biophys Res Commun 1991;179(1):57–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_26">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Yabushita</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines</ArticleTitle>
                <JournalTitle>J Obstet Gynaecol Res</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>529</FirstPage>
                <LastPage>39</LastPage>
                <Occurrence Type="PID">
                  <Handle>9037942</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhsVOisbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yabushita H, et al. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res 1996;22(6):529–39.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_26">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fujioka</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>160</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>247</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>9628658</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitFal</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fujioka T, et al. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 1998;160(1):247–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_26">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nagakura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1986</Year>
                <ArticleTitle Language="En">Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line</ArticleTitle>
                <JournalTitle>Kidney Int</JournalTitle>
                <VolumeID>29</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>834</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>3012186</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XitVWitrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nagakura K, et al. Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int 1986;29(4):834–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_26">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Higashimoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">1 Alpha,25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>5A</IssueID>
                <FirstPage>2653</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8917365</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XntVeqsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Higashimoto Y, et al. 1 Alpha,25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 1996;16(5A):2653–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_26">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Zugmaier</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>73</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1341</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8645577</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XksF2kt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zugmaier G, et al. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 1996;73(11):1341–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR101_26">
              <CitationNumber>101</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Getzenberg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>50</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>999</FirstPage>
                <LastPage>1006</LastPage>
                <Occurrence Type="PID">
                  <Handle>9426741</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c%2FovVWntQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Getzenberg RH, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50(6):999–1006.</BibUnstructured>
            </Citation>
            <Citation ID="CR102_26">
              <CitationNumber>102</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TE</Initials>
                  <FamilyName>Hedlund</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Moffatt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>277</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>8836163</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmtFWlurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58(3):277–88.</BibUnstructured>
            </Citation>
            <Citation ID="CR103_26">
              <CitationNumber>103</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Peehl</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>54</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>805</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>7508338</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhsFCrs74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peehl DM, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54(3):805–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR104_26">
              <CitationNumber>104</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Human prostate cancer cells: inhibition of proliferation by vitamin D analogs</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>3A</IssueID>
                <FirstPage>1077</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>8074453</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXmvFait7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schwartz GG, et al. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994;14(3A):1077–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR105_26">
              <CitationNumber>105</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Skowronski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Peehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>136</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>20</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7530193</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXjt1Knsbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995;136(1):20–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR106_26">
              <CitationNumber>106</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Skowronski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Peehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>132</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1952</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>7682937</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXksVKmsrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132(5):1952–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR107_26">
              <CitationNumber>107</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Zhuang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>126</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>83</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>9027366</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhsleqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhuang SH, et al. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126(1):83–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR108_26">
              <CitationNumber>108</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Shabahang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">The effect of 1,25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor</ArticleTitle>
                <JournalTitle>Ann Surg Oncol</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>144</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8646514</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK283js1GnsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shabahang M, et al. The effect of 1,25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Ann Surg Oncol 1996;3(2):144–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR109_26">
              <CitationNumber>109</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hara</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>1A</IssueID>
                <FirstPage>321</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>11299756</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXivFCmsLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hara K, et al. Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res 2001;21(1A):321–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR110_26">
              <CitationNumber>110</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Tokuumi</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Correlation between the concentration of 1,25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3</ArticleTitle>
                <JournalTitle>Nippon Seikeigeka Gakkai Zasshi</JournalTitle>
                <VolumeID>69</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>181</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>7782656</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXls1Sjtro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tokuumi Y. Correlation between the concentration of 1,25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3. Nippon Seikeigeka Gakkai Zasshi 1995;69(4):181–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR111_26">
              <CitationNumber>111</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Celli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Treves</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Stio</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation</ArticleTitle>
                <JournalTitle>Neurochem Int</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>117</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>10213069</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitlGksLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Celli A, Treves C, Stio M. Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation. Neurochem Int 1999;34(2):117–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR112_26">
              <CitationNumber>112</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TD</Initials>
                  <FamilyName>Veenstra</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells</ArticleTitle>
                <JournalTitle>Brain Res Dev Brain Res</JournalTitle>
                <VolumeID>99</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>53</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>9088565</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXht1KgsL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Veenstra TD, et al. Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res 1997;99(1):53–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR113_26">
              <CitationNumber>113</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Naveilhan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors?</ArticleTitle>
                <JournalTitle>J Neurosci Res</JournalTitle>
                <VolumeID>37</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>271</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8151734</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhsFCrsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Naveilhan P, et al. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? J Neurosci Res 1994;37(2):271–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR114_26">
              <CitationNumber>114</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Colston</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Colston</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>108</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1083</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>6257495</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3MXhtlaksLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981;108(3):1083–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR115_26">
              <CitationNumber>115</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Hershberger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2644</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10363987</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1ymtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hershberger PA, et al. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59(11):2644–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR116_26">
              <CitationNumber>116</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TF</Initials>
                  <FamilyName>McGuire</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <IssueID>28</IssueID>
                <FirstPage>26365</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>11331275</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlsVKntr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McGuire TF, Trump DL, Johnson CS, et al. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276(28):26365–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR117_26">
              <CitationNumber>117</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Berger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1988</Year>
                <ArticleTitle Language="En">Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>607</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>2842365</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXlsVGmur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berger U, et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988;67(3):607–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR118_26">
              <CitationNumber>118</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MF</Initials>
                  <FamilyName>Holick</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Vitamin D: a millennium perspective</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>296</FirstPage>
                <LastPage>307</LastPage>
                <Occurrence Type="PID">
                  <Handle>12520530</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXntlyksQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Holick MF. Vitamin D: a millennium perspective. J Cell Biochem 2003;88(2):296–307.</BibUnstructured>
            </Citation>
            <Citation ID="CR119_26">
              <CitationNumber>119</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Campbell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HP</Initials>
                  <FamilyName>Koeffler</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Toward therapeutic intervention of cancer by vitamin D compounds</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>182</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9016994</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhtlGls7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997;89(3):182–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR120_26">
              <CitationNumber>120</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Sheikh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Rochefort</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garcia</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1899</FirstPage>
                <LastPage>905</LastPage>
                <Occurrence Type="PID">
                  <Handle>7478620</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXptlOksLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 1995;11(9):1899–905.</BibUnstructured>
            </Citation>
            <Citation ID="CR121_26">
              <CitationNumber>121</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>QM</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Studzinski</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>56</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>264</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8542578</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmtVGnsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996;56(2):264–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR122_26">
              <CitationNumber>122</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Zhuang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KL</Initials>
                  <FamilyName>Burnstein</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>139</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1197</FirstPage>
                <LastPage>207</LastPage>
                <Occurrence Type="PID">
                  <Handle>9492054</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhtlCntrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139(3):1197–207.</BibUnstructured>
            </Citation>
            <Citation ID="CR123_26">
              <CitationNumber>123</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Hershberger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1043</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>11309356</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjs1elt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hershberger PA, et al. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7(4):1043–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR124_26">
              <CitationNumber>124</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YC</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JY</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Hung</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>28</IssueID>
                <FirstPage>4856</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>15064717</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkvVOisrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huang YC, Chen JY, Hung WC. Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Oncogene 2004;23(28):4856–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR125_26">
              <CitationNumber>125</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Inoue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kamiyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sakai</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>274</VolumeID>
                <IssueID>45</IssueID>
                <FirstPage>32309</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>10542271</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXnt12jurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999;274(45):32309–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR126_26">
              <CitationNumber>126</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>144</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>749</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>12586749</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhslCqs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lin R, et al. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinology 2003;144(3):749–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR127_26">
              <CitationNumber>127</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KL</Initials>
                  <FamilyName>Burnstein</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>278</VolumeID>
                <IssueID>47</IssueID>
                <FirstPage>46862</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12954644</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXovFKksb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278(47):46862–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR128_26">
              <CitationNumber>128</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kobayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hashimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yoshikawa</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>196</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>487</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>8216332</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXisVahtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kobayashi T, Hashimoto K, Yoshikawa K. Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 1993;196(1):487–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR129_26">
              <CitationNumber>129</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>Fan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line</ArticleTitle>
                <JournalTitle>Cancer Invest</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>280</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7743381</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmsVKjtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fan FS, Yu WC. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest 1995;13(3):280–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR130_26">
              <CitationNumber>130</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Hager</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck</ArticleTitle>
                <JournalTitle>Acta Otolaryngol</JournalTitle>
                <VolumeID>121</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>103</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11270487</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFykt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hager G, et al. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 2001;121(1):103–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR131_26">
              <CitationNumber>131</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Jensen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1370</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>11463860</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlslSgsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jensen SS, et al. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001;15(8):1370–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR132_26">
              <CitationNumber>132</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Yen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Varvayanis</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation</ArticleTitle>
                <JournalTitle>Exp Cell Res</JournalTitle>
                <VolumeID>214</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>250</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8082728</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlslKitLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yen A, Varvayanis S. Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp Cell Res 1994;214(1):250–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR133_26">
              <CitationNumber>133</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Matsumoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1990</Year>
                <ArticleTitle Language="En">Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>166</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>916</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>2405860</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXhtFakurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matsumoto K, et al. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 1990;166(2):916–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR134_26">
              <CitationNumber>134</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Reitsma</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1983</Year>
                <ArticleTitle Language="En">Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>306</VolumeID>
                <IssueID>5942</IssueID>
                <FirstPage>492</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>6689055</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXjtlGrsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reitsma PH, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983;306(5942):492–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR135_26">
              <CitationNumber>135</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Tong</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>2119</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>10070321</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitVWnsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tong WM, et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998;34(13):2119–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR136_26">
              <CitationNumber>136</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Drivdahl</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>72</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7531847</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXksFans70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drivdahl RH, et al. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995;26(2):72–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR137_26">
              <CitationNumber>137</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Scharla</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>129</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>3139</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>1720089</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xhs1akuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Scharla SH, et al. 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology 1991;129(6):3139–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR138_26">
              <CitationNumber>138</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Vink-van Wijngaarden</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>32A</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>842</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9081364</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK283ntlGisw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vink-van Wijngaarden T, et al. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur J Cancer 1996;32A(5):842–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR139_26">
              <CitationNumber>139</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Haugen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">1 Alpha,25-dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor beta 2 release</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>229</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>618</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>8954947</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xns1egtrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Haugen JD, et al. 1 Alpha,25-dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor beta 2 release. Biochem Biophys Res Commun 1996;229(2):618–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR140_26">
              <CitationNumber>140</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">1 Alpha,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>239</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>734</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9367838</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXnsVKksbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu Y, et al. 1 Alpha,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res Commun 1997;239(3):734–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR141_26">
              <CitationNumber>141</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Elstner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>55</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>2822</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>7796409</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmsFyks7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Elstner E, et al. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55(13):2822–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR142_26">
              <CitationNumber>142</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Studzinski</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants</ArticleTitle>
                <JournalTitle>Exp Cell Res</JournalTitle>
                <VolumeID>232</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>376</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>9168815</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXivFeis7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Studzinski GP, et al. Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. Exp Cell Res 1997;232(2):376–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR143_26">
              <CitationNumber>143</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Qiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Tuohimaa</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells</ArticleTitle>
                <JournalTitle>FEBS Lett</JournalTitle>
                <VolumeID>577</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>451</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>15556626</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVSrtLbN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Qiao S, Tuohimaa P. Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells. FEBS Lett 2004;577(3):451–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR144_26">
              <CitationNumber>144</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Qiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Tuohimaa</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>319</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>358</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>15178414</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkslSjt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Qiao S, Tuohimaa P. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochem Biophys Res Commun 2004;319(2):358–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR145_26">
              <CitationNumber>145</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BY</Initials>
                  <FamilyName>Bao</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>3350</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>15048085</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjtlChu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bao BY, et al. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004;23(19):3350–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR146_26">
              <CitationNumber>146</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Guzey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kitada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Reed</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>667</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>12479363</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFSmtL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002;1(9):667–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR147_26">
              <CitationNumber>147</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Modzelewski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Hershberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumors in vitro</ArticleTitle>
                <JournalTitle>Proc AACR</JournalTitle>
                <VolumeID>40</VolumeID>
                <FirstPage>580</FirstPage>
              </BibArticle>
              <BibUnstructured>Modzelewski RA, Hershberger PA, Johnson CS, et al. Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumors in vitro. Proc AACR 1999;40:580.</BibUnstructured>
            </Citation>
            <Citation ID="CR148_26">
              <CitationNumber>148</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Elstner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>56</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>3570</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8758928</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xks1elsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Elstner E, et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996;56(15):3570–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR149_26">
              <CitationNumber>149</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>James</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Mackay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Colston</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>395</FirstPage>
                <LastPage>401</LastPage>
                <Occurrence Type="PID">
                  <Handle>8903423</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmslahtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996;58(4):395–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR150_26">
              <CitationNumber>150</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Pepper</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>101</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2454</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>12446453</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXivVWgtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pepper C, et al. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003;101(7):2454–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR151_26">
              <CitationNumber>151</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>INRW</Initials>
                  <FamilyName>Sergeev</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ChapterTitle Language="En">1,25-dihydroxyvitamin D3, intracellular Ca2+ and apoptosis in breast cancer cell lines</ChapterTitle>
                <BibEditorName>
                  <Initials>AW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>R</Initials>
                  <FamilyName>Bouillon</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>M</Initials>
                  <FamilyName>Thomasset</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Vitamin D chemistry, biology and clinical applications of the steroid hormone</BookTitle>
                <PublisherName>University of California</PublisherName>
                <PublisherLocation>Riverside, CA</PublisherLocation>
                <FirstPage>473</FirstPage>
                <LastPage>4</LastPage>
              </BibChapter>
              <BibUnstructured>Sergeev INRW, Norman AW. 1,25-dihydroxyvitamin D3, intracellular Ca2+ and apoptosis in breast cancer cell lines. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D chemistry, biology and clinical applications of the steroid hormone. Riverside, CA: University of California; 1997. p. 473–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR152_26">
              <CitationNumber>152</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Simboli-Campbell</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>367</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>8903420</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xmslahtrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Simboli-Campbell M, et al. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58(4):367–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR153_26">
              <CitationNumber>153</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Vandewalle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Wattez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lefebvre</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium</ArticleTitle>
                <JournalTitle>Cancer Lett</JournalTitle>
                <VolumeID>97</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>99</FirstPage>
                <LastPage>106</LastPage>
                <Occurrence Type="PID">
                  <Handle>7585485</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXoslGnsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vandewalle B, Wattez N, Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 1995;97(1):99–106.</BibUnstructured>
            </Citation>
            <Citation ID="CR154_26">
              <CitationNumber>154</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Wagner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax</ArticleTitle>
                <JournalTitle>Exp Eye Res</JournalTitle>
                <VolumeID>77</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>1</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12823982</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXkvVCgtbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wagner N, et al. 1,25-Dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res 2003;77(1):1–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR155_26">
              <CitationNumber>155</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IS</Initials>
                  <FamilyName>Mathiasen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Lademann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Jaattela</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>4848</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>10519395</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmslWkt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 1999;59(19):4848–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR156_26">
              <CitationNumber>156</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Polek</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>144</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>50</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>12488329</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhtFSgsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Polek TC, et al. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003;144(1):50–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR157_26">
              <CitationNumber>157</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Galbiati</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>144</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1832</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>12697689</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjt1WisL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Galbiati F, et al. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology 2003;144(5):1832–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR158_26">
              <CitationNumber>158</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Narvaez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Welsh</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>9101</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11053435</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXisVCnurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001;276(12):9101–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR159_26">
              <CitationNumber>159</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Xie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>James</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Colston</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells</ArticleTitle>
                <JournalTitle>J Endocrinol</JournalTitle>
                <VolumeID>154</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>495</FirstPage>
                <LastPage>504</LastPage>
                <Occurrence Type="PID">
                  <Handle>9379127</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXlvVCqsrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xie SP, James SY, Colston KW. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997;154(3):495–504.</BibUnstructured>
            </Citation>
            <Citation ID="CR160_26">
              <CitationNumber>160</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Bernardi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>4164</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>11751517</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XltFShug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bernardi RJ, et al. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001;7(12):4164–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR161_26">
              <CitationNumber>161</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Bernardi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>143</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2508</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>12072382</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XltVymsLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bernardi RJ, et al. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002;143(7):2508–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR162_26">
              <CitationNumber>162</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Rocker</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>106</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>157</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>7895902</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXitlaksrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rocker D, et al. 1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol 1994;106(1–2):157–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR163_26">
              <CitationNumber>163</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Murthy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Weigel</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>282</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>15042604</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkt12is74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Murthy S, Weigel NL. 1Alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 2004;59(3):282–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR164_26">
              <CitationNumber>164</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IN</Initials>
                  <FamilyName>Sergeev</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Rhoten</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Regulation of intracellular calcium in human breast cancer cells</ArticleTitle>
                <JournalTitle>Endocrine</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>321</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10221599</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhsFWhtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sergeev IN, Rhoten WB. Regulation of intracellular calcium in human breast cancer cells. Endocrine 1998;9(3):321–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR165_26">
              <CitationNumber>165</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IN</Initials>
                  <FamilyName>Sergeev</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>89–90</VolumeID>
                <IssueID>1–5</IssueID>
                <FirstPage>419</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>15225813</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sergeev IN. Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. J Steroid Biochem Mol Biol 2004;89–90(1–5):419–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR166_26">
              <CitationNumber>166</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <IssueID>51</IssueID>
                <FirstPage>53213</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>15485861</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVKqurbM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jiang F, et al. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004;279(51):53213–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR167_26">
              <CitationNumber>167</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Haes</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>663</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>12858333</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De Haes P, et al. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J Cell Biochem 2003;89(4):663–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR168_26">
              <CitationNumber>168</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Mantell</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo</ArticleTitle>
                <JournalTitle>Circ Res</JournalTitle>
                <VolumeID>87</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>214</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>10926872</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlsFygs7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mantell DJ, et al. 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87(3):214–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR169_26">
              <CitationNumber>169</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Majewski</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis</ArticleTitle>
                <JournalTitle>J Investig Dermatol Symp Proc</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>97</FirstPage>
                <LastPage>101</LastPage>
                <Occurrence Type="PID">
                  <Handle>9627702</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xkt1emtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Majewski S, et al. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996;1(1):97–101.</BibUnstructured>
            </Citation>
            <Citation ID="CR170_26">
              <CitationNumber>170</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yudoh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Matsuno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kimura</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma</ArticleTitle>
                <JournalTitle>J Lab Clin Med</JournalTitle>
                <VolumeID>133</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>120</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9989763</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhsFSjsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yudoh K, Matsuno H, Kimura T. 1Alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999;133(2):120–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR171_26">
              <CitationNumber>171</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">1 Alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>727</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>9298581</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmtlSjsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schwartz GG, et al. 1 Alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997;6(9):727–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR172_26">
              <CitationNumber>172</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Sung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>164</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>133</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>11026565</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlvV2msbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sung V, Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000;164(1–2):133–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR173_26">
              <CitationNumber>173</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BY</Initials>
                  <FamilyName>Bao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YF</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases</ArticleTitle>
                <JournalTitle>Carcinogenesis</JournalTitle>
                <VolumeID>27</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>32</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>15987715</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtlCmsbjE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bao BY, Yeh SD, Lee YF. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006;27(1):32–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR174_26">
              <CitationNumber>174</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Hansen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">1 Alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro</ArticleTitle>
                <JournalTitle>Clin Exp Metastasis</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>195</FirstPage>
                <LastPage>202</LastPage>
                <Occurrence Type="PID">
                  <Handle>8194194</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlsV2ksbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hansen CM, et al. 1 Alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994;12(3):195–202.</BibUnstructured>
            </Citation>
            <Citation ID="CR175_26">
              <CitationNumber>175</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Young</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence</ArticleTitle>
                <JournalTitle>Cancer Immunol Immunother</JournalTitle>
                <VolumeID>41</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>37</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>7641218</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXoslars7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Young MR, et al. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 1995;41(1):37–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR176_26">
              <CitationNumber>176</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Koli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Keski-Oja</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells</ArticleTitle>
                <JournalTitle>Cell Growth Differ</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>221</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10775039</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXisFOmtbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Koli K, Keski-Oja J. 1Alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000;11(4):221–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR177_26">
              <CitationNumber>177</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Campbell</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin</ArticleTitle>
                <JournalTitle>J Mol Endocrinol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>15</FirstPage>
                <LastPage>27</LastPage>
                <Occurrence Type="PID">
                  <Handle>9278857</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXltlehtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Campbell MJ, et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997;19(1):15–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR178_26">
              <CitationNumber>178</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Gonzalez-Sancho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Alvarez-Dolado</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Munoz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells</ArticleTitle>
                <JournalTitle>FEBS Lett</JournalTitle>
                <VolumeID>426</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>225</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9599013</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXisFamu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A, et al. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett 1998;426(2):225–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR179_26">
              <CitationNumber>179</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>134</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>9450573</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXosleltA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yu WD, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998;90(2):134–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR180_26">
              <CitationNumber>180</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Weekly high-dose calcitriol and docetaxel in advanced prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <IssueID>4 Suppl 15</IssueID>
                <FirstPage>49</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>11685729</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXotVemtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, et al. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR181_26">
              <CitationNumber>181</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Moffatt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WU</Initials>
                  <FamilyName>Johannes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>695</FirstPage>
                <LastPage>703</LastPage>
                <Occurrence Type="PID">
                  <Handle>10100724</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitVyitr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999;5(3):695–703.</BibUnstructured>
            </Citation>
            <Citation ID="CR182_26">
              <CitationNumber>182</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ahmed</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>756</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>12131364</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XmtFWhur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ahmed S, et al. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 2002;168(2):756–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR183_26">
              <CitationNumber>183</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BW</Initials>
                  <FamilyName>Light</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>3759</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>9288784</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXlvFent7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Light BW, et al. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57(17):3759–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR184_26">
              <CitationNumber>184</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wieder</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">1,25-Dihydroxyvitamin D3 and all-trans retinoic acid promote apoptosis and sensitize breast cancer cells to the effects of chemotherapeutic agents</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>107a</FirstPage>
              </BibArticle>
              <BibUnstructured>Wieder R, et al. 1,25-Dihydroxyvitamin D3 and all-trans retinoic acid promote apoptosis and sensitize breast cancer cells to the effects of chemotherapeutic agents. Proc Am Soc Clin Oncol 1998;17:107a.</BibUnstructured>
            </Citation>
            <Citation ID="CR185_26">
              <CitationNumber>185</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Sundaram</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells</ArticleTitle>
                <JournalTitle>Breast Cancer Res Treat</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>1</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>11079153</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXot1Skuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sundaram S, et al. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 2000;63(1):1–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR186_26">
              <CitationNumber>186</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Torres</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells</ArticleTitle>
                <JournalTitle>Mol Cell Biochem</JournalTitle>
                <VolumeID>208</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>157</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>10939640</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXltl2iu7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Torres R, et al. Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells. Mol Cell Biochem 2000;208(1–2):157–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR187_26">
              <CitationNumber>187</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Koga</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Sutherland</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>4A</IssueID>
                <FirstPage>455</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>1654997</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XosFA%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Koga M, Sutherland RL. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 1991;39(4A):455–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR188_26">
              <CitationNumber>188</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Guzey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Sattler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>DeLuca</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>249</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>735</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>9731207</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlslGhs7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guzey M, Sattler C, DeLuca HF. Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochem Biophys Res Commun 1998;249(3):735–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR189_26">
              <CitationNumber>189</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Peehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Interaction of nuclear receptor ligands with the vitamin D signaling pathway in prostate cancer</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>307</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>15663994</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXkvVShsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):307–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR190_26">
              <CitationNumber>190</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ikeda</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>739</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>12939463</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXms1GktLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ikeda N, et al. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2003;2(8):739–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR191_26">
              <CitationNumber>191</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Anzano</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">1 Alpha,25-dihydroxy-16-ene-23-yne-26, 27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>54</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1653</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8137276</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXis1SktLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Anzano MA, et al. 1 Alpha,25-dihydroxy-16-ene-23-yne-26, 27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54(7):1653–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR192_26">
              <CitationNumber>192</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Welsh</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens</ArticleTitle>
                <JournalTitle>Biochem Cell Biol</JournalTitle>
                <VolumeID>72</VolumeID>
                <IssueID>11–12</IssueID>
                <FirstPage>537</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>7654327</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmtFShu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994;72(11–12):537–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR193_26">
              <CitationNumber>193</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Abe-Hashimoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2534</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8495416</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXks1alsrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Abe-Hashimoto J, et al. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993;53(11):2534–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR194_26">
              <CitationNumber>194</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Christensen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment</ArticleTitle>
                <JournalTitle>Breast Cancer Res Treat</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>53</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>15039597</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXisVWgtLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Christensen GL, et al. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat 2004;85(1):53–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR195_26">
              <CitationNumber>195</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Gavrilov</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Steiner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shany</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>3425</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16101159</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXps1Kgtb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gavrilov V, Steiner M, Shany S. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res 2005;25(5):3425–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR196_26">
              <CitationNumber>196</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Moreno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Krishnan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>97</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>31</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>16024246</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFyks7jP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005;97(1–2):31–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR197_26">
              <CitationNumber>197</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Moreno</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>7917</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>16140963</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslahsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moreno J, et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005;65(17):7917–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR198_26">
              <CitationNumber>198</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hsiao</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Functional expression of human p21(WAF1/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>233</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>329</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="PID">
                  <Handle>9144534</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXivVGrtbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsiao M, et al. Functional expression of human p21(WAF1/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. Biochem Biophys Res Commun 1997;233(2):329–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR199_26">
              <CitationNumber>199</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Dunlap</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">1Alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>746</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>12915889</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmtFKqsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dunlap N, et al. 1Alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 2003;89(4):746–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR200_26">
              <CitationNumber>200</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Polar</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Effect of the vitamin D3 analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>415</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>12690516</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjsVOqsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Polar MK, et al. Effect of the vitamin D3 analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother Pharmacol 2003;51(5):415–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR201_26">
              <CitationNumber>201</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>DeMasters</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the vitamin D3 analog EB 1089</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>365</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>15698541</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXptleksw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>DeMasters GA, et al. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the vitamin D3 analog EB 1089. J Steroid Biochem Mol Biol 2004;92(5):365–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR202_26">
              <CitationNumber>202</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Osborn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>195</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>21224117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BC3M7gs1Skuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Osborn JL, et al. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1(5):195–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR203_26">
              <CitationNumber>203</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Gross</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>159</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2035</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9598513</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXms1Omur8%3D</Handle>
                </Occurrence>
                <BibComments>Discussion 2039–40</BibComments>
              </BibArticle>
              <BibUnstructured>Gross C, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159(6):2035–9. Discussion 2039–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR204_26">
              <CitationNumber>204</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DC</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1339</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>10389917</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXkt1Oqurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith DC, et al. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999;5(6):1339–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR205_26">
              <CitationNumber>205</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Munar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Henner</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>91</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2431</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11413535</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXltVOnsb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001;91(12):2431–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR206_26">
              <CitationNumber>206</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Muindi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>72</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>648</FirstPage>
                <LastPage>59</LastPage>
                <Occurrence Type="PID">
                  <Handle>12496746</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXltF2qtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Muindi JR, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002;72(6):648–59.</BibUnstructured>
            </Citation>
            <Citation ID="CR207_26">
              <CitationNumber>207</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>7794</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16278401</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtF2isL7E</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, et al. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 2005;11(21):7794–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR208_26">
              <CitationNumber>208</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol, in patients with cancer</ArticleTitle>
                <JournalTitle>Proc Am Assoc Cancer Res</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>A404</FirstPage>
              </BibArticle>
              <BibUnstructured>Beer TM, Javle MM, Henner WD and Trump DL. Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol, in patients with cancer. Proc Amer Assoc Cancer Res 2004;45:404.</BibUnstructured>
            </Citation>
            <Citation ID="CR209_26">
              <CitationNumber>209</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>100</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1868</FirstPage>
                <LastPage>75</LastPage>
                <Occurrence Type="PID">
                  <Handle>15112267</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkt1Sgs7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Morris MJ, et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 2004;100(9):1868–75.</BibUnstructured>
            </Citation>
            <Citation ID="CR210_26">
              <CitationNumber>210</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Tiffany</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>174</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>888</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>16093981</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXnt1yrsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tiffany NM, et al. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005;174(3):888–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR211_26">
              <CitationNumber>211</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>97</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1217</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>12599228</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXisVKhtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, et al. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003;97(5):1217–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR212_26">
              <CitationNumber>212</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>106</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2136</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>16598750</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkvFOnt78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trump DL, et al. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006;106(10):2136–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR213_26">
              <CitationNumber>213</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>123</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12506180</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWqsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21(1):123–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR214_26">
              <CitationNumber>214</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>669</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>17308271</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjt1Kgu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR215_26">
              <CitationNumber>215</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Attia</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2437</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>18413835</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXkvFGmtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Attia S, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008;14(8):2437–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR216_26">
              <CitationNumber>216</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Upton</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone</ArticleTitle>
                <JournalTitle>Nephrol Dial Transplant</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>750</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12637645</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXit1yqsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Upton RA, et al. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003;18(4):750–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR217_26">
              <CitationNumber>217</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Sjoden</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1985</Year>
                <ArticleTitle Language="En">1 Alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat</ArticleTitle>
                <JournalTitle>Proc Soc Exp Biol Med</JournalTitle>
                <VolumeID>178</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>432</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>3871952</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2M7ktVemuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sjoden G, et al. 1 Alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985;178(3):432–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR218_26">
              <CitationNumber>218</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garzotto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Katovic</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Am J Clin Oncol</JournalTitle>
                <VolumeID>27</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>535</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>15596926</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXps1altbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004;27(5):535–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR219_26">
              <CitationNumber>219</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Flaig</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>107</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>266</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16779800</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xnsl2mtL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Flaig TW, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006;107(2):266–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR220_26">
              <CitationNumber>220</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>102</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1601</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18782306</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhtVWktLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chan JS, et al. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int 2008;102(11):1601–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR221_26">
              <CitationNumber>221</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Kissmeyer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1087</FirstPage>
                <LastPage>97</LastPage>
                <Occurrence Type="PID">
                  <Handle>9175713</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjtFersro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kissmeyer AM, et al. Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 1997;53(8):1087–97.</BibUnstructured>
            </Citation>
            <Citation ID="CR222_26">
              <CitationNumber>222</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bouillon</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Non-hypercalcemic pharmacological aspects of vitamin D analogs</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>50</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>577</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>7669059</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnvFCjsL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bouillon R, et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol 1995;50(5):577–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR223_26">
              <CitationNumber>223</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bouillon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WH</Initials>
                  <FamilyName>Okamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Structure–function relationships in the vitamin D endocrine system</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>200</FirstPage>
                <LastPage>57</LastPage>
                <Occurrence Type="PID">
                  <Handle>7781594</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmtFWisrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bouillon R, Okamura WH, Norman AW. Structure–function relationships in the vitamin D endocrine system. Endocr Rev 1995;16(2):200–57.</BibUnstructured>
            </Citation>
            <Citation ID="CR224_26">
              <CitationNumber>224</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Gulliford</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>78</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>6</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>9662243</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXksVynt7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gulliford T, et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998;78(1):6–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR225_26">
              <CitationNumber>225</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TR</Initials>
                  <FamilyName>Evans</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>86</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>680</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>11875725</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjtVKjsLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Evans TR, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86(5):680–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR226_26">
              <CitationNumber>226</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Dalhoff</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>252</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12865912</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsVaktbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dalhoff K, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89(2):252–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR227_26">
              <CitationNumber>227</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bower</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Topical calcipotriol treatment in advanced breast cancer</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>337</VolumeID>
                <IssueID>8743</IssueID>
                <FirstPage>701</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="PID">
                  <Handle>1672178</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M7mtlaisA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bower M, et al. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991;337(8743):701–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR228_26">
              <CitationNumber>228</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>2820</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12231522</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XnvVWisLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liu G, et al. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 2002;8(9):2820–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR229_26">
              <CitationNumber>229</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wieder</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>445</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>14586212</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXotleit74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wieder R, et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Invest New Drugs 2003;21(4):445–52.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
